

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2021 OF THE CONDITION AND AFFAIRS OF THE

Empire HealthChoice HMO, Inc.

	(Current) (Prior)	• •	e _95433_ Employer's I		
Organized under the Laws of	New York	, s	State of Domicile or Port of E	ntry	NY
Country of Domicile		United States of	of America		
Licensed as business type:		Health Maintenanc	e Organization		
Is HMO Federally Qualified?	Yes[]No[X]				
Incorporated/Organized	03/05/1996		Commenced Business	03/1	9/1996
Statutory Home Office	9 Pine Street, 14th Floor			New York, NY, US 10005	
	(Street and Number)		(City o	r Town, State, Country and	Zip Code)
Main Administrative Office		9 Pine Street,			
	New York, NY, US 10005	(Street and N	,	212-563-5570	
(City or	Town, State, Country and Zip Code)			Area Code) (Telephone Nun	ber)
Mail Address	9 Pine Street, 14th Floor			New York, NY, US 10005	1
	(Street and Number or P.O. Box)		(City o	r Town, State, Country and	Zip Code)
Primary Location of Books and	Records	220 Virginia	Avenue		
	Indianandia IN LIG 46004	(Street and N	Number)	000 500 0400	
(City or	Indianapolis, IN, US 46204 Town, State, Country and Zip Code)	,		866-583-6182 Area Code) (Telephone Num	iber)
Internet Website Address		www.empirel	oluo com	, , ,	,
internet Website Address		www.empired	olde.com		
Statutory Statement Contact	Leigh Barre (Name)	ett		317-488-6816 (Area Code) (Telephone	Number)
	leigh.barrett@anthem.com	91		317-488-6200	Number)
	(E-mail Address)			(FAX Number)	
		OFFICE	RS		
President, Chairperson and	Alam January Administra		_	Ed. (Bista)	Commande Mariella
Chief Executive Officer _	Alan James Murray Jay Harry Wagner		Treasurer _ Assistant Secretary _		(enneth Noble nes O'Keeffe
Secretary _	out than tragitor			Tation	neo o reene
Vincent Edward Sche	er, Assistant Treasurer	OTHE	iR .		
		DIDECTORS OF	TRUCTEE		
Alan Jam	es Murray	DIRECTORS OR Lois Susan F		Patrick Ja	mes O'Keeffe
Raul Guille	rmo Smith #				
State of	Indiana	SS			
County of	Johnson				
all of the herein described as statement, together with relate condition and affairs of the sa in accordance with the NAIC rules or regulations require respectively. Furthermore, the	Jo Jurray	said reporting entity, therein contained, and iod stated above, and bunting Practices and accounting practices bed officers also inclu	free and clear from any lier nexed or referred to, is a full of its income and deduction Procedures manual except and procedures, accordinates the related correspondi- ient. The electronic filing ma	s or claims thereon, except and true statement of all the statement of all the statement of the period er to the extent that: (1) state g to the best of their inform g electronic filing with the type requested by various reposed by: DocuSigned by: E598440298764E.	as herein stated, and that this assets and liabilities and of the ided, and have been completed aw may differ; or, (2) that state mation, knowledge and belief NAIC, when required, that is are gulators in lieu of or in addition
Subscribed and sworn to be for			a. Is this an original filir b. If no, 1. State the amendr 2. Date filed 3. Number of pages	nent number	Yes [X] No []

Rita F. Gentry Executive Assistant 1/17/2029

> Rita F. Gentry Notary Public SEAL Johnson County, State of Indiana My Commission Expires January 17, 2029 Commission No: NP0641321

ASSETS

			Current Year		Prior Year
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1.	Bonds (Schedule D)	320,250,647		320,250,647	311,064,048
2.	Stocks (Schedule D):				
	2.1 Preferred stocks			0	0
	2.2 Common stocks			0	0
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens			0	0
	3.2 Other than first liens			0	0
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$				
	encumbrances)			0	0
	4.2 Properties held for the production of income (less				
	\$ encumbrances)			0	0
	4.3 Properties held for sale (less \$				
	encumbrances)			0	0
5.	Cash (\$10,802,737 , Schedule E - Part 1), cash equivalents				
	(\$0 , Schedule E - Part 2) and short-term				
	investments (\$, Schedule DA)	10,802,737		10,802,737	28,493,763
6.	Contract loans, (including \$ premium notes)			0	0
	Derivatives (Schedule DB)				
	Other invested assets (Schedule BA)				
	Receivables for securities				
	Securities lending reinvested collateral assets (Schedule DL)				
11.	Aggregate write-ins for invested assets	0	0	0	0
12.	Subtotals, cash and invested assets (Lines 1 to 11)	346,234,008	0	346,234,008	349,940,400
13.	Title plants less \$ charged off (for Title insurers				
	only)			0	0
14.	Investment income due and accrued	2,841,886		2,841,886	2,939,671
15.	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection	8,112,263	1,716,320	6,395,943	5,923,724
	15.2 Deferred premiums and agents' balances and installments booked but				
	deferred and not yet due (including \$				
	earned but unbilled premiums)			0	0
	15.3 Accrued retrospective premiums (\$1,596,905) and				
	contracts subject to redetermination (\$20,523,539)	22,120,444		22,120,444	23,018,437
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers			0	0
	16.2 Funds held by or deposited with reinsured companies			0	0
	16.3 Other amounts receivable under reinsurance contracts				
	Amounts receivable relating to uninsured plans		· ·		·
18.1	Current federal and foreign income tax recoverable and interest thereon	13,763,052		13,763,052	9,250,200
18.2	Net deferred tax asset			0	0
19.	Guaranty funds receivable or on deposit			0	0
20.	Electronic data processing equipment and software			0	0
21.	Furniture and equipment, including health care delivery assets				
	(\$)				
	Net adjustment in assets and liabilities due to foreign exchange rates				
	Receivables from parent, subsidiaries and affiliates				
	Health care (\$ $5,792,640$) and other amounts receivable				
25.	Aggregate write-ins for other than invested assets	31,800,382	756,265	31,044,117	27,342,305
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	AA5 000 A71	1/ 102 160	/Q1 027 202	425 202 A04
27	Protected Cell Accounts (Lines 12 to 25)	440,230,47 I	14, 193, 109	431,037,302	420,392,401
27.	Accounts			0	0
28.	Total (Lines 26 and 27)	445,230,471	14, 193, 169	431,037,302	425,392,401
	DETAILS OF WRITE-INS				
1101.					
1102.					
1103.					
	Summary of remaining write-ins for Line 11 from overflow page		0	0	.0
	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0		0
	Medicare Receivables	24 997 827		24,997,827	19 775 377
	City Income Tax Recoverable			4,054,393	
	Premium Tax Recoverable	, ,		1,228,407	*
	Summary of remaining write-ins for Line 25 from overflow page	, ,		763,490	
	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	31.800.382	756,265		
∠ეყყ.	Totals (Lines 2001 tilla 2009 bias 2030)(Fille 50 above)	31,000,362	100,200	J 31,044,11/	21,342,303

LIABILITIES, CAPITAL AND SURPLUS

	LIADILITIES, CAP		Current Year	,	Prior Year
	<u> </u>	1	2	3	4
				-	T. ()
	• • • • • • • • • • • • • • • • • • • •	Covered	Uncovered	Total	Total
	Claims unpaid (less \$0 reinsurance ceded)				122, 196, 630
	Accrued medical incentive pool and bonus amounts				
	Jnpaid claims adjustment expenses	2,186,844		2,186,844	2,674,150
4. <i>A</i>	Aggregate health policy reserves, including the liability of				
	\$0 for medical loss ratio rebate per the Public				
	Health Service Act	1,527,610		1,527,610	18,579,698
5. <i>A</i>	Aggregate life policy reserves			0	0
6. F	Property/casualty unearned premium reserves			0	0
7.	Aggregate health claim reserves			0	1,030
	Premiums received in advance				
	General expenses due or accrued				
	Current federal and foreign income tax payable and interest thereon				
	(including \$ on realized capital gains (losses))			0	0
	Net deferred tax liability				0
	Ceded reinsurance premiums payable				
	Amounts withheld or retained for the account of others			· · ·	
	Remittances and items not allocated	3,222,505		3,222,505	3,559,413
14. E	Borrowed money (including \$ current) and				
	interest thereon \$ (including				
	\$ current)			0	0
15. <i>A</i>	Amounts due to parent, subsidiaries and affiliates	139,337,162		139,337,162	59,856,905
16. [Derivatives			0	0
	Payable for securities				0
	Payable for securities lending				10.382.589
	Funds held under reinsurance treaties (with \$, ,		, ,	,,,,,
	authorized reinsurers, \$				
	reinsurers and \$			0	0
				0	0
	Reinsurance in unauthorized and certified (\$				0
	companies				
	Net adjustments in assets and liabilities due to foreign exchange rates				0
22. l	Liability for amounts held under uninsured plans			0	0
	Aggregate write-ins for other liabilities (including \$2,854,302				
	current)				
24.	Total liabilities (Lines 1 to 23)	285,360,692	0	285,360,692	245, 190,660
	Aggregate write-ins for special surplus funds			0	0
26. (Common capital stock	XXX	XXX	2	2
	Preferred capital stock				
	Gross paid in and contributed surplus				
	Surplus notes.				
	Aggregate write-ins for other than special surplus funds				
	Jnassigned funds (surplus)				
	- ' ' '			(31, 130,700)	(40,490,000)
	Less treasury stock, at cost:				
3	32.1 shares common (value included in Line 26				
	\$	XXX	XXX		
3	32.2 shares preferred (value included in Line 27				
	\$				
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)	xxx	XXX	145,676,610	180,201,741
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	431,037,302	425,392,401
	DETAILS OF WRITE-INS				
	Other Premium Liability	1 064 303		1 064 303	280,510
	Miscellaneous Medicare Liabilities				949,315
	Escheat Liability				765,564
					,
	Summary of remaining write-ins for Line 23 from overflow page		0		441,456
	Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	3,602,985	0	3,602,985	2,436,845
2503		xxx	xxx		
2598.	Summary of remaining write-ins for Line 25 from overflow page	xxx	XXX	0	0
	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	xxx	XXX	0	0
	Required Reserves			94,833,398	118 700 549
	icquired neserves				
	Summary of remaining write-ins for Line 30 from overflow page				0
3099.	Totals (Lines 3001 thru 3003 plus 3098)(Line 30 above)	XXX	XXX	94,833,398	118,700,549

STATEMENT OF REVENUE AND EXPENSES

	STATEMENT OF REVENUE AF	Current '		Prior Year
		1	2	3
		Uncovered	Total	Total
1.	Member Months	XXX	708,959	898,761
2.	Net premium income (including \$ non-health premium income)			
3.	Change in unearned premium reserves and reserve for rate credits	XXX	(3,454,546)	2,863,580
4.	Fee-for-service (net of \$ medical expenses)	XXX	0	
5.	Risk revenue	XXX	0	
6.	Aggregate write-ins for other health care related revenues	xxx	0	0
7.	Aggregate write-ins for other non-health revenues	xxx	0	0
8.	Total revenues (Lines 2 to 7)	XXX		952,467,973
	Hospital and Medical:			
9.	Hospital/medical benefits		535,994,080	643,366,771
10.	Other professional services		19,506,195	26,112,583
11.	Outside referrals		91,981,506	59,798,654
12.	Emergency room and out-of-area			28,467,417
13.	Prescription drugs			61,632,989
	Aggregate write-ins for other hospital and medical.			, ,
14.				
15.	Incentive pool, withhold adjustments and bonus amounts			
16.	Subtotal (Lines 9 to 15)	0		841,246,491
17.	Less: Net reinsurance recoveries		0	
18.	Total hospital and medical (Lines 16 minus 17)			841,246,491
19.	Non-health claims (net)			
20.	Claims adjustment expenses, including \$32, 189,072 cost containment expenses			54,590,226
21.	General administrative expenses		55,648,901	92,710,145
22.	Increase in reserves for life and accident and health contracts (including \$			
	increase in reserves for life only)		(17,640,696)	(33, 112, 103)
23.	Total underwriting deductions (Lines 18 through 22)	0	811, 173, 472	955,434,759
24.	Net underwriting gain or (loss) (Lines 8 minus 23)	xxx	(55,960,836)	(2,966,786)
25.	Net investment income earned (Exhibit of Net Investment Income, Line 17)		8,661,365	8,662,295
26.	Net realized capital gains (losses) less capital gains tax of \$			
27.	Net investment gains (losses) (Lines 25 plus 26)			11,142,065
28.	Net gain or (loss) from agents' or premium balances charged off [(amount recovered		, ,	, ,
20.	\$		(580, 473)	(210 585)
00	,,		60,476	(210,363)
29.	Aggregate write-ins for other income or expenses			(100,404)
30.	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	XXX	(47,451,986)	7,776,230
31.	Federal and foreign income taxes incurred			(2,379,942)
32.	Net income (loss) (Lines 30 minus 31)	xxx	(33,487,501)	10, 156, 172
02.	DETAILS OF WRITE-INS	7001	(66, 161, 661)	,,
0601.	DETAILS OF WATE-INS	YYY		
0602.		XXX		
0603				
0698.	Summary of remaining write-ins for Line 6 from overflow page		0	0
0699.	Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	0	0
0701.	Totals (Lines 9001 tilla 9005 plus 9050)(Line 9 above)		Ü	<u> </u>
0701.		XXX		
0703				
0798.	Summary of remaining write-ins for Line 7 from overflow page		0	0
0799.	Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
1401.	Pool Recoveries - Stop Loss			(301 376)
1401.	ruui necuvei ies – Stup Luss			(301,370)
1402.				
1403.	Summary of remaining write-ins for Line 14 from overflow page			0
1496.	Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	(54,879)	(301,376)
2901.	Miscellaneous (expense) income	-	60,476	(301,370)
2901.				(100,404)
2903	Summon, of romaining write ine for Line 20 from everflow needs		0	^
2998.	Summary of remaining write-ins for Line 29 from overflow page			
2999.	Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	U	60,476	(188,464)

STATEMENT OF REVENUE AND EXPENSES (Continued)

		1 Current Year	2 Prior Year
		Current Year	Piloi Year
	CAPITAL AND SURPLUS ACCOUNT		
33. Capit	tal and surplus prior reporting year	190 201 741	157 155 770
	ncome or (loss) from Line 32		
	nge in valuation basis of aggregate policy and claim reserves		
	nge in net unrealized capital gains (losses) less capital gains tax of \$		
	nge in net unrealized foreign exchange capital gain or (loss)		
	nge in net deferred income tax		
	nge in nonadmitted assets		
	nge in unauthorized and certified reinsurance		
41. Char	nge in treasury stock	0	0
42. Char	nge in surplus notes	0	0
43. Cum	ulative effect of changes in accounting principles		
44. Capit	tal Changes:		
44.1	Paid in	0	0
44.2	Transferred from surplus (Stock Dividend)	0	0
44.3	Transferred to surplus		
45. Surpl	lus adjustments:		
45.1	Paid in	0	0
45.2	Transferred to capital (Stock Dividend)		
45.3	Transferred from capital		
46. Divid	lends to stockholders		
47. Aggr	egate write-ins for gains or (losses) in surplus	0	0
48. Net c	change in capital and surplus (Lines 34 to 47)	(34,525,131)	23,045,971
49. Capit	tal and surplus end of reporting period (Line 33 plus 48)	145,676,610	180,201,741
DET	AILS OF WRITE-INS		
4701			
4702			
4703			
4798. Sum	mary of remaining write-ins for Line 47 from overflow page	0	0
4799. Total	ls (Lines 4701 thru 4703 plus 4798)(Line 47 above)	0	0

CASH FLOW

	OAOIII EOII	1	2
		•	_
		Current Year	Prior Year
	Cash from Operations		
1.	Premiums collected net of reinsurance		953,888,306
2.	Net investment income		11,544,219
3.	Miscellaneous income		0
4.	Total (Lines 1 through 3)		965,432,525
5.	Benefit and loss related payments	757,281,702	792,879,404
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7.	Commissions, expenses paid and aggregate write-ins for deductions	109,353,426	148, 138, 648
8.	Dividends paid to policyholders		
9.	Federal and foreign income taxes paid (recovered) net of \$223,747 tax on capital gains (losses)	(9,227,886)	3,756,144
10.	Total (Lines 5 through 9)	857,407,242	944,774,196
11.	Net cash from operations (Line 4 minus Line 10)	(89,273,202)	20,658,329
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
	12.1 Bonds	64 682 757	95 453 423
	12.2 Stocks		
	12.3 Mortgage loans		
	12.4 Real estate		0
	12.5 Other invested assets		0
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		
			19,992)
	12.7 Miscellaneous proceeds		05 400 401
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	54,082,737	95,433,431
13.	Cost of investments acquired (long-term only):	70.047.000	00 400 000
	13.1 Bonds		
	13.2 Stocks		0
	13.3 Mortgage loans		0
	13.4 Real estate		0
	13.5 Other invested assets		0
	13.6 Miscellaneous applications	4,798,035	6,546,266
	13.7 Total investments acquired (Lines 13.1 to 13.6)	80,845,701	99,737,158
14.	Net increase (decrease) in contract loans and premium notes	0	0
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(16,162,944)	(4,303,727)
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes	0	0
	16.2 Capital and paid in surplus, less treasury stock	0	0
	16.3 Borrowed funds	0	0
	16.4 Net deposits on deposit-type contracts and other insurance liabilities		0
	16.5 Dividends to stockholders		0
	16.6 Other cash provided (applied)		3,492,680
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)		3,492,680
		51,110,120	0, 102,000
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	(17,691,026)	19,847,282
19.	Cash, cash equivalents and short-term investments:		
	19.1 Beginning of year		8,646,481
	19.2 End of year (Line 18 plus Line 19.1)	10,802,737	28,493,763

Note: Supplemental disclosures of cash flow information for non-cash transactions:		

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

		1	2	3	4	5	6	7	8	9	10
			Comprehensive	Medicare	Dental	Vision	Federal Employees Health	Title XVIII	Title XIX		Other
		Total	(Hospital & Medical)	Supplement	Only	Only	Benefits Plan	Medicare	Medicaid	Other Health	Non-Health
1.	Net premium income		17,230,584		,	0	.0				
2.	Change in unearned premium reserves and reserve for rate credit	(3,454,546)						(3,454,546)			
3.	Fee-for-service (net of \$	0						(=, -, -, -, -, -, -, -, -, -, -, -, -, -,			
,	medical expenses)										XXX XXX
5.	Aggregate write-ins for other health care related										
6.	revenues	0	0	0		0	.00	0	0	0	XXX
_	revenues	0	XXX	XXX	XXX	xxx	xxx	XXX	XXX	xxx	0
	Total revenues (Lines 1 to 6)	755,212,636	17,230,584	0		J	.00	737,982,052	0	0	0
8.	Hospital/medical benefits	535,994,080	10,566,603			J	.0	525,427,477			XXX
9.	Other professional services	19,506,195	606,252					18,899,943			XXX
10.	Outside referrals Emergency room and out-of-area	91,981,506	358,913					91,622,593			XXX
11.		24,504,414	1,518,072 432,754					22,986,342 39.351,952		(4.004)	XXXXXX
12.	Prescription drugs							39,351,952		(1,334)	
13.		(54,879)	(54,879)			J	.υυ	······································	u	0	XXX
14.	Incentive pool, withhold adjustments and bonus amounts	15,755,756	192,712					15,563,044	0	(1.334)	XXX XXX
15.	Subtotal (Lines 8 to 14)	727,470,444	13,620,427	υ		J	.υ υ	713,851,351	0	, , , ,	
16.	Net reinsurance recoveries	0	40.000.407					713.851.351		0	XXX XXX
17.	Total medical and hospital (Lines 15 minus 16)		13,620,427	U .		J	.0		U	(1,334)	
18.	Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
19.	\$32, 189,072 cost containment expenses	45,694,823	1,022,868					44,671,955			
20.	General administrative expenses	55,648,901	1,245,688					54,403,213			
21.	Increase in reserves for accident and health contracts	(17,640,696)	(3,839,232)					(13,801,464)			XXX
22.	Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
23.	Total underwriting deductions (Lines 17 to 22)	811, 173, 472	12,049,751	0		0	.00	799, 125, 055	0	(1,334)	0
24.	Total underwriting gain or (loss) (Line 7 minus Line 23)	(55,960,836)	5,180,833	0		0	0 0	(61, 143, 003)	0	1,334	0
0501.	DETAILS OF WRITE-INS										xxx
0502.											XXX
0503.											XXX
0598.	Summary of remaining write-ins for Line 5 from overflow page	0	0	0		n	0	0	0	0	XXX
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0		0	0 0	0	0	0	XXX
0601.	Totals (Ellies coor till a coop plus coop) (Ellie a above)		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	////
0602.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0603.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
	Summary of remaining write-ins for Line 6 from overflow				XXX				XXX	XXX	
0699.	page	 0	XXX	XXX	XXX	XXX	XXX XXX	XXX	XXX	XXX	را م
	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above) Pool Recoveries - Stop Loss	(54.879)	(54.879)	^^^	^^^	^^^	^^^	^^^	^^^	^^^	VVV
1301.		(54,8/9)	(54,8/9)			-				·····	XXX
1302.			 							+	XXX
1303. 1398.	Summary of remaining write-ins for Line 13 from		†							+	XXX
	overflow page	0	0	0		0	.0 0.	0	0	0	XXX
1399.	Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above)	(54,879)	(54,879)	0		0	0	0	0	0	XXX

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

FART 1-FREINIONIS	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
Comprehensive (hospital and medical)	17,230,584	0	0	17,230,584
2. Medicare Supplement	0	0	0	0
3. Dental only	0	0	0	0
4. Vision only	0	0	0	0
5. Federal Employees Health Benefits Plan	0	0	0	0
6. Title XVIII - Medicare	741,436,598	0	0	741,436,598
7. Title XIX - Medicaid	0	0	0	0
8. Other health	0	0	0	0
9. Health subtotal (Lines 1 through 8)	758,667,182	0	0	758,667,182
10. Life	0		0	0
11. Property/casualty	0			0
12. Totals (Lines 9 to 11)	758,667,182	0	0	758,667,182

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

Perfect during the year. Table Comprisement Supplement Depth				PART 2 - CLAI	IMS INCURRED DU	RING THE TEAR					
Part		1	2	3	4	5		7	8	9	10
1. Pyments during the year: 1.1 Direct 1.1 Direct 1.2 Reinsurance assumed 0.0 1.2 Reinsurance assumed 1.3 Reinsurance coesied 0.0 1.4 Reinsurance coesied 0.0 1.5 Reinsurance coesied 0.0 1.6 Reinsurance assumed 1.6 Reinsurance coesied 0.0 1.7 Reinsurance coesied 0.0 1.7 Reinsurance assumed 1.1 Reinsurance coesied 0.0 1.1 Direct 1		Total			Dental Only	Vision Only	Health	XVIII	XIX	Other Health	
1.1 Direct	1 Payments during the year:	· Otal	(Freepital at Mearcal)	Саррістіст	Donital Only	1.0.0 0	Dononto i idii	modiodio	ourou.u	o anor i rodiar	
1.2 Reinsurance assumed 1.3 Reinsurance coded 2.5 Paid medical inventive pools and bonuses 1.11.45.994 2.30, 143 3. Claim isolatily December 31, current year from Part 2A; 3. Claim isolatily December 31, current year from Part 2A; 3. Reinsurance assumed 91,172,785 2.540,283 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		745 855 707	16 808 935	0	٥	0	0	729 046 682	0	an	
1.3 Reinsurance ceded			10,000,300			0	0				
1. Net		٥	0	Λ	Λ	Λ	0	Λ		Λ	
2. Paid medical incentive pools and bonuses 11 45;984 203,143 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		745 055 707			 ^ l			720 046 692			
3. Claim lability December 31, current year from Part 2N: 3. 1 Direct sussumed 9 1, 172, 785 2, 540, 283 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0					۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰		0			90	
3.1 Preet 91.172,785 2.540,283 0 0 0 0 0 0 88,632,502 0 0 0 0 3.2 Reinsurance assumed 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		11,425,994	203, 143				0	11,222,801	0		
3.2 Reinsurance assumed 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		04 470 705	0 540 000	0	0	0	0	00 000 500	0		,
3.3 Reinsurance ceded		91,1/2,/85	2,540,283			0	0	88,632,502	0		٠
3.4 Net 4. Claim reserve December 31, current year from Part 2D: 4.1 Direct 4. Plant reserve December 31, current year from Part 2D: 4.2 Reinsurance assumed 4.4 Net 6.		0				0	0	0	0		٠
4. Claim reserve December 31, current year from Part 2D: 4. 1 Pirect 4. 2 Reinsurance assumed 4. 3 Reinsurance assumed 4. 3 Reinsurance assumed 4. 3 Reinsurance assumed 5. Accrued medical incentive pools and bonuses, current year 5. Accrued medical incentive pools and bonuses, current year 6. Reinsurance assumed 7. A mounts recoverable from reinsurers December 31, current year 8. Claim faibility December 31, prior year from Part 2A: 8. 1 Direct 8. 2 Reinsurance assumed 9. Claim reserve December 31, prior year from Part 2D: 9. 1 Direct 9. 2 Reinsurance assumed 9. 2 Reinsurance assumed 9. 2 Reinsurance assumed 9. 2 Reinsurance assumed 9. 3 Reinsurance assumed 9. 2 Reinsurance assumed 9. 3 Reinsurance assumed 9. 3 Reinsurance assumed 9. 4 Reinsurance assumed 9. 3 Reinsurance assumed 9. 4 Reinsurance assumed 9. 4 Reinsurance assumed 9. 5 Reinsurance assumed 9. 6 Reinsurance assumed 9. 6 Reinsurance assumed 9. 7 Reinsurance assumed 9. 8 Reinsurance assumed 9. 8 Reinsurance assumed 9. 8 Reinsurance assumed 9. 9 Reinsurance assumed 9. 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		0	0	0	0	0	0	0	0	0	
4.1 Direct 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		91,1/2,/85	2,540,283	0	0	0	0	88,632,502	0	0	
4.2 Reinsurance assumed 4.3 Reinsurance ceded 5. Accrued medical incentive pools and bonuses, current year 6. Reinsurance pools and bonuses, current year receivables (a) 7. Amounts recoverable from reinsurers December 31, current year 8. Claim liability December 31, prior year from Part 2D: 9. Claim reserve December 31, prior year from Part 2D: 9. Claim reserve December 31, prior year from Part 2D: 9. Claim reserve December 31, prior year from Part 2D: 9. Claim reserve December 31, prior year from Part 2D: 9. Claim reserve December 31, prior year from Part 2D: 9. Claim reserve December 31, prior year from Part 2D: 9. Claim reserve December 31, prior year from Part 2D: 9. Claim reserve December 31, prior year from Part 2D: 9. Claim reserve December 31, prior year from Part 2D: 9. Claim reserve December 31, prior year from Part 2D: 9. Claim reserve December 31, prior year from Part 2D: 9. Claim reserve December 31, prior year from Part 2D: 9. Reinsurance assumed 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		_									
4.3 Reinsurance ceded 4.4 Net 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.		0									
4.4 Net 4. Net 4. Net 5. Accrued medical incentive pools and bonuses, current year 5. Accrued medical incentive pools and bonuses, current year 6. Exercised Section 1. Section		0									
5. Accrued medical incentive pools and bonuses, current year 6. Net healthcare receivables (a) 3, 116, 144 3, 097, 443 0, 0 0, 0 0, 0 0 19,277 0, (576) 7. Amounts recoverable from reinsures December 31, current year . 8. Claim liability December 31, prior year from Part 2A: 8.1 Direct 122, 196, 630 2, 823, 031 0 0 0 0 0 0 0 193, 371, 599 0 2,000 8.3 Reinsurance assumed 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		0									
year		0	0	0	0	0	0	0	0	0	
7. Amounts recoverable from reinsurers December 31, current year. 8. Claim liability December 31, prior year from Part 2A: 8.1 Direct 9. Reinsurance assumed 9. Claim cested 9. Claim liability December 31, prior year from Part 2A: 122, 196, 630 122, 196, 630 122, 196, 630 123, Reinsurance essumed 10. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0		26,259,533	323,938	0	0	0	0	25,935,595	0	0	
7. Amounts recoverable from reinsurers December 31, current year. 8. Claim liability December 31, prior year from Part 2A: 8.1 Direct 9. Reinsurance assumed 9. Claim cested 9. Claim liability December 31, prior year from Part 2A: 122, 196, 630 122, 196, 630 122, 196, 630 123, Reinsurance essumed 10. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0	Net healthcare receivables (a)	3, 116, 144	3,097,443	0	0	0	0	19,277	0	(576)	
8. Claim liability December 31, prior year from Part 2A: 8.1 Direct 8.2 Reinsurance assumed 9. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Amounts recoverable from reinsurers December 31, current year	0						,			
8.1 Direct	8. Claim liability December 31, prior year from Part 2A:										
8.2 Reinsurance assumed 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		122.196.630	2.823.031	0	0	0	0	119.371.599	0	2.000	(
8.3 Reinsurance ceded	8.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	(
8.4 Net		0	0	0	0	0	0	0	0	0	(
9. Claim reserve December 31, prior year from Part 2D: 9.1 Direct 9.2 Reinsurance assumed 9.3 Reinsurance ceded 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		122 196 630	2 823 031	0	0	0	0	119 371 599	0	2 000	(
9.1 Direct 1,030 1,029 0			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						-	, , , ,	
9.2 Reinsurance assumed 0 <td></td> <td>1.030</td> <td>1.029</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>1</td> <td>0</td> <td>0</td> <td>(</td>		1.030	1.029	0	0	0	0	1	0	0	(
9.3 Reinsurance ceded 0		0	,						0		
9.4 Net		0	0	0	0	0	0	0	0	0	(
10. Accrued medical incentive pools and bonuses, prior year 21,929,771 334,369 0 0 0 0 0 21,595,402 0 0 0 0 0 1 1. Amounts recoverable from reinsurers December 31, prior year 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		1 030	1 029	0	0	0	0	1	0	0	(
11. Amounts recoverable from reinsurers December 31, prior year 0 <t< td=""><td></td><td></td><td></td><td>n</td><td>n</td><td>n</td><td>n</td><td>21 595 402</td><td>n </td><td>n</td><td>······································</td></t<>				n	n	n	n	21 595 402	n	n	······································
prior year 0		21,020,771	001,000	Ů	, ,	·		21,000,102	•	Ů	•
12. Incurred Benefits: 12.1 Direct 711,714,688 13,427,715 0 0 0 698,288,307 0 (1,334) 12.2 Reinsurance assumed 0 0 0 0 0 0 0 0 0 0 12.3 Reinsurance ceded 0 0 0 0 0 0 0 0 0 0 12.4 Net 711,714,688 13,427,715 0 0 0 0 698,288,307 0 (1,334)		0	0	0	0	0	0	0	0	0	(
12.1 Direct 711,714,688 13,427,715 0 0 0 698,288,307 0 (1,334) 12.2 Reinsurance assumed 0 0 0 0 0 0 0 0 0 12.3 Reinsurance ceded 0 0 0 0 0 0 0 0 0 12.4 Net 711,714,688 13,427,715 0 0 0 0 698,288,307 0 (1,334)				-		<u>-</u>			<u> </u>	-	
12.2 Reinsurance assumed 0		711.714.688	13.427.715	0	0	0	0	698.288.307	0	(1,334)	
12.3 Reinsurance ceded 0 0 0 0 0 0 0 0 12.4 Net 711,714,688 13,427,715 0 0 0 0 698,288,307 0 (1,334)		0	0	0	0	0	0	0	0	0	(
12.4 Net 711,714,688 13,427,715 0 0 0 0 698,288,307 0 (1,334)		0	0	0	0	0	0	0	0	0	(
	-	711.714.688	13.427.715	0	0	0	0	698.288.307	0	(1,334)	(
					n	n			0	(1,001)	

(a) Excludes \$ loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

			FAILT ZA - CLAIM	5 2 // (B121111 211B)						
	1	2	3	4	5	6 Federal Employees	7 Title	8 Title	9	10
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Health Benefits Plan	XVIII Medicare	XIX Medicaid	Other Health	Other Non-Health
Reported in Process of Adjustment:										
1.1 Direct	28,377,563	1,237,653					27, 139,910			
1.2 Reinsurance assumed	0									
1.3 Reinsurance ceded	0									
1.4 Net	28,377,563	1,237,653	0	0	0	0	27, 139,910	0	0	0
Incurred but Unreported:										
2.1 Direct	62,795,222	1,302,630					61,492,592			
2.2 Reinsurance assumed	0									
2.3 Reinsurance ceded	0									
2.4 Net	62,795,222	1,302,630	0	0	0	0	61,492,592	0	0	0
Amounts Withheld from Paid Claims and Capitations:										
3.1 Direct	0									
3.2 Reinsurance assumed	0									
3.3 Reinsurance ceded	0									
3.4 Net	0	0	0	0	0	0	0	0	0	0
0.1100					-	•				
4. TOTALS:										
4.1 Direct	91,172,785	2,540,283	0	0	0	0	88,632,502	0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
4.4 Net	91, 172, 785	2,540,283	0	0	0	0	88,632,502	0	0	0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

PART 2B - ANALTSIS OF CLAIMS UNFAID - P				nd Claim Liability	5	6
	Claims Paid I	Ouring the Year 2	December 31	of Current Year 4		Estimated Claim
		_		·		Reserve and Claim
	On Claims Incurred Prior to January 1	On Claims Incurred	On Claims Unpaid December 31 of	On Claims Incurred	Claims Incurred In Prior Years	Liability December 31 of
Line of Business	of Current Year	During the Year	Prior Year	During the Year	(Columns 1 + 3)	Prior Year
Comprehensive (hospital and medical)	4,686,452	18 , 787 , 687	707,897	1,832,386	5,394,349	2,824,060
Medicare Supplement					0	0
3. Dental Only					0	0
4. Vision Only					0	0
5. Federal Employees Health Benefits Plan					0	0
6. Title XVIII - Medicare	96,718,155	639,946,295	2,645,330	85,987,172	99,363,485	119,371,600
7 Title XIX - Medicaid					0	0
8. Other health	1,179	(513)			1,179	2,000
9. Health subtotal (Lines 1 to 8)	101,405,786	658,733,469	3,353,227	87,819,558	104,759,013	122, 197,660
10. Healthcare receivables (a)	3,492,024	13,907,668			3,492,024	0
11. Other non-health					0	0
12. Medical incentive pools and bonus amounts	5,304,758	6, 121, 236	22,987,555	3,271,978	28,292,313	21,929,771
13. Totals (Lines 9 - 10 + 11 + 12)	103,218,520	650,947,037	26,340,782	91,091,536	129,559,302	144, 127, 431

(a) Excludes \$ loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

		Cumulative Net Amounts Paid						
		1	2	3	4	5		
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021		
1.	Prior	42,672	41,829	41,664	40,728	40,728		
2.	2017	467,564	520,563	521,602	524,449	525,242		
3.	2018	XXX	93,556	102,312	102,405	102,840		
4.	2019	XXX	XXX	80,539	90,353	90 , 127		
5.	2020	XXX	XXX	XXX	21,632	22,282		
6.	2021	XXX	XXX	XXX	XXX	12,263		

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuse Outstanding at End of Year							
Year in Which Losses Were Incurred	1 2 3 4 2017 2018 2019 2020							
1. Prior	45,374	42,607	41,697	41,118	2021 40,728			
2. 2017	526,053	522,587	524,604	524,511	525,633			
3. 2018	XXX	105,347	102,581	102,724	102,851			
4. 2019	XXX	XXX	90,465	90,488	90,554			
5. 2020	XXX	XXX	XXX	23,887	22,465			
6. 2021	XXX	XXX	XXX	XXX	14,115			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017	561,974	525,242	23,948	4.6	549,190	97.7	390	5	549,585	97.8
2.	2018	124,461	102,840	6,041	5.9	108,881	87.5	12		108,893	87.5
3.	2019	105,315	90 , 127	3,008	3.3	93 , 135	88.4	427	3	93,565	88.8
4.	2020	39,598	22,282	2,606	11.7	24,888	62.9	183	3	25,074	63.3
5.	2021	17,231	12,263	851	6.9	13,114	76.1	1,853	27	14,994	87.0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XVIII

	Cumulative Net Amounts Paid							
	1	2	3	4	5			
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021			
1. Prior	87,715	90,167		87,254				
2. 2017	651,644	735,688	735,422	735,141	735,471			
3. 2018	XXX	731,613	801,629	805,118	805,242			
4. 2019	XXX	XXX	716,294	796,760	798,596			
5. 2020	XXX	XXX	XXX	676,920	776, 195			
6. 2021	XXX	XXX	XXX	XXX	638,685			

Section B - Incurred Health Claims - Title XVIII

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Outstanding at End of Year						
	1 2 3 4						
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021		
1. Prior	91,418	89,427		87,257	87,254		
2. 2017	740,969	737,209	737 , 248	735,229	735,473		
3. 2018	XXX	810,358	803,953	806,681	809,772		
4. 2019	XXX	XXX	794,665	803,457	807, 165		
5. 2020	XXX	XXX	XXX	809,537	788,424		
6. 2021	XXX	XXX	XXX	XXX	727,923		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2017	722,297	735,471	26,342	3.6	761,813	105.5	2	0	761,815	105.5
2. 2018	867,320	805,242	36,590	4.5	841,832	97.1	4,530	1	846,363	97.6
3. 2019	871,982	798,596	46,977	5.9	845,573	97.0	8,568	2	854 , 143	98.0
4. 2020	912,811	776, 195	50,356	6.5	826,551	90.6	12,229	61	838,841	91.9
5. 2021	737,982	638,685	38,259	6.0	676,944	91.7	89,238	2,085	768,267	104.1

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)

(\$000 Omitted) Section A - Paid Health Claims - Other

		Cumulative Net Amounts Paid							
		1	2	3	4	5			
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021			
1.	Prior	6	5	5	5	5			
2.	2017	276	278	278	278	278			
3.	2018	XXX	244	256	256	256			
4.	2019	XXX	XXX	251	258	258			
5.	2020	XXX	XXX	XXX	79	79			
6.	2021	XXX	XXX	XXX	XXX	0			

Section B - Incurred Health Claims - Other

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bor Outstanding at End of Year							
	1	4	5					
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021			
1. Prior	7	5	5	5	5			
2. 2017	282	278	278	278	278			
3. 2018	XXX	253	257	256	256			
4. 2019	XXX	XXX	255	258	258			
5. 2020	XXX	XXX	XXX	81	79			
6. 2021	XXX	XXX	XXX	XXX				

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Other

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017	311	278	2	0.7	280	90.0			280	90.0
2.	2018	313	256	3	1.2	259	82.7			259	82.7
3.	2019	294	258	2	0.8	260	88.4			260	88.4
4.	2020		79	1	1.3	80	137.9			80	137.9
5.	2021				0.0	0	0.0			0	0.0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Grand Total

		Cumulative Net Amounts Paid						
		1	2	3	4	5		
	Year in Which Losses Were Incurred	2017	2018	2019	2020	2021		
1.	Prior	130,393	132,001	130 , 175	127,987	127,987		
2.	2017	1,119,484	1,256,529	1,257,302	1,259,868	1,260,991		
3.	2018	XXX	825,413	904 , 197	907,779	908,338		
4.	2019	XXX	XXX	797,084	887,371	888,981		
5.	2020	XXX	XXX	XXX	698,631	798,556		
6.	2021	XXX	XXX	XXX	XXX	650,948		

Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonu Outstanding at End of Year							
Vancia Which I areas Wass lawred	1 2 3 4							
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021			
1. Prior	136,799	132,039	130,211	128,380	127,987			
2. 2017	1,267,304	1,260,074	1,262,130	1,260,018	1,261,384			
3. 2018	XXX	915,958	906,791	909,661	912,879			
4. 2019	XXX	XXX	885,385	894,203	897,977			
5. 2020	XXX	XXX	XXX	833,505	810,968			
6. 2021	XXX	XXX	XXX	XXX	742,038			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2017	1,284,582	1,260,991	50,292	4.0	1,311,283	102.1	392	5	1,311,680	102.1
2. 2018	992,094	908,338	42,634	4.7	950,972	95.9	4,542	1	955,515	96.3
3. 2019	977,591	888,981	49,987	5.6	938,968	96.0	8,995	5	947,968	97.0
4. 2020	952,467	798,556	52,963	6.6	851,519	89.4	12,412	64	863,995	90.7
5. 2021	755,213	650,948	39,110	6.0	690,058	91.4	91,091	2,112	783,261	103.7

UNDERWRITING AND INVESTMENT EXHIBIT

	PART 2D - A	GGREGATE RESER			NTRACTS ONLY				
	1 Total	2 Comprehensive (Hospital & Medical)	3 Medicare Supplement	4 Dental Only	5 Vision Only	6 Federal Employees Health Benefits Plan	7 Title XVIII Medicare	8 Title XIX Medicaid	9 Other
Unearned premium reserves		(Hospital & Medical)	опрыетыт	Dental Only	Vision Only	Deficitio Fian	Wedicare	iviedicaid	Other
Additional policy reserves (a)	0								
Reserve for future contingent benefits	0								
Reserve for rate credits or experience rating refunds (including	0								
	1 507 610						1 507 610		
\$				0	0		1,527,610		
Aggregate write-ins for other policy reserves			0			0		0	ى
7. Reinsurance ceded	1,027,010		0	0	0	0	1,527,610	0	
	0								
8. Totals (Net)(Page 3, Line 4)		0	0	0	0	0	1,527,610	0	C
Present value of amounts not yet due on claims									
10. Reserve for future contingent benefits									
11. Aggregate write-ins for other claim reserves	0		0	0	0	0	0	0	
12. Totals (gross)		0	0	0	0	0	0	0	
13. Reinsurance ceded	0								
14. Totals (Net)(Page 3, Line 7)	0	0	0	0	0	0	0	0	(
DETAILS OF WRITE-INS									
0501.									
0502.									
0503.									
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	
0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	C
1101.									
1102.									
1103.									
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	
1199. Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	C

(a) Includes \$ _____ premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

			YSIS OF EXPENSE			_
		Claim Adjustme 1 Cost Containment Expenses	2 Other Claim Adjustment Expenses	3 General Administrative Expenses	4 Investment Expenses	5 Total
1.	Rent (\$ for occupancy of	Схрепзез	Ехрепзез	Схрепаеа	Ехрепзез	Total
	own building)	498 134	435 305	22 049	18	955 506
2.	Salary, wages and other benefits					
3.	Commissions (less \$	10,070,041		14, 100,700	11,004	90,440,002
3.	ceded plus \$ assumed)	0		11 036 063	0	11 036 063
4	Legal fees and expenses			1,936,063		
4. 5.	Certifications and accreditation fees					
6.	Auditing, actuarial and other consulting services					
7.	Traveling expenses			119,434		
	Marketing and advertising					14,924,119
8.	Postage, express and telephone			688,394		
9.	Printing and office supplies			65,093		
10.						
11.	Occupancy, depreciation and amortization			0		
12.	Equipment	205	1,991	207,895	1/1	210,262
13.	Cost or depreciation of EDP equipment and software	140,715	118,099	859,356	709	1,118,879
14.	Outsourced services including EDP, claims, and other services	12,765,078	2,204,288	10,055,988	8,291	25,033,645
15.	Boards, bureaus and association fees			77,224		
16.	Insurance, except on real estate					
17.	Collection and bank service charges					
18.	Group service and administration fees					
19.	Reimbursements by uninsured plans					
20.	Reimbursements from fiscal intermediaries			0		
21.	Real estate expenses			266,615		
22.	Real estate taxes			45,661		45,661
23.	Taxes, licenses and fees:					
20.	23.1 State and local insurance taxes	0		(4,276,436)	0	(4,276,436
	23.2 State premium taxes			346,052	0	346,052
	23.3 Regulatory authority licenses and fees			436,505		445,206
	23.4 Payroll taxes			923,794	0	0.057.040
	23.5 Other (excluding federal income and real					
	estate taxes)			275,518	0	275,518
24.	Investment expenses not included elsewhere		0.474.040	0	312,452	312,452
25.	Aggregate write-ins for expenses	303,987	2,174,318	1,841,417	1,518	4,321,240
26.	Total expenses incurred (Lines 1 to 25)		13,505,751			(-, , , ,
27.	Less expenses unpaid December 31, current year		2,186,844	835,566		3,022,410
28. 29.	Add expenses unpaid December 31, prior year Amounts receivable relating to uninsured plans,		2,674,150	1,950,187		4,624,337
30.	Amounts receivable relating to uninsured plans,			424,963		424,963
31.	current year			2,958,744		2,958,744
	minus 29 plus 30) DETAILS OF WRITE-INS	32,189,072	13,993,057	59,297,303	350,348	105,829,780
2501	Miscellaneous Expenses	303 987	2 174 318	1,841,417	1 518	4,321,240
2501.			2, 177,010		1,510	
2502. 2503.						
	Summary of remaining write-ins for Line 25 from overflow page		n	n	n	٥
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25		0 474 040	1 044 447	4 540	4 204 040
a) Indiu	above) des management fees of \$	303,987 affiliates and \$	2,174,318	1,841,417 n-affiliates.	1,518	4,321,240

EXHIBIT OF NET INVESTMENT INCOME

		1	2
		Collected During Year	Earned During Year
1.	U.S. government bonds		82,869
1.1	Bonds exempt from U.S. tax		
1.2	Other bonds (unaffiliated)	' '	8,802,062
1.3	Bonds of affiliates	(a)0	
2.1	Preferred stocks (unaffiliated)	(b)0	
2.11	Preferred stocks of affiliates		
2.2	Common stocks (unaffiliated)	0	0
2.21	Common stocks of affiliates	0	0
3.	Mortgage loans	(c)0	
4.	Real estate		0
5	Contract Loans	0	0
6	Cash, cash equivalents and short-term investments	(e)17,303	17,303
7	Derivative instruments		0
8.	Other invested assets	0	0
9.	Aggregate write-ins for investment income	108,896	109,479
10.	Total gross investment income	9,109,498	9,011,713
11.	Investment expenses		
12.	Investment taxes, licenses and fees, excluding federal income taxes		(g)0
13.	Interest expense		(h)
14.	Depreciation on real estate and other invested assets		(i)
15.	Aggregate write-ins for deductions from investment income		0
16.	Total deductions (Lines 11 through 15)		350,348
17.	Net investment income (Line 10 minus Line 16)		8,661,365
	DETAILS OF WRITE-INS		
0901.	Miscellaneous Income	81,500	81,500
0902.	Securities Lending	27,396	27,979
0903.	-		
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	108,896	109,479
1501.			
1502.			
1503.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		0
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		0
	Entra track Control of		

(a) Includes \$	136,811	accrual of discount less \$3, 143,894	amortization of premium and less \$	101,590	paid for accrued interest on purchases.
(b) Includes \$	0	accrual of discount less \$0	amortization of premium and less \$	0	paid for accrued dividends on purchases
(c) Includes \$	0	accrual of discount less \$0	amortization of premium and less \$		paid for accrued interest on purchases.
(d) Includes \$		for company's occupancy of its own building	s; and excludes \$i	nterest on encun	nbrances.
(e) Includes \$		accrual of discount less \$	amortization of premium and less \$		paid for accrued interest on purchases.
(f) Includes \$		accrual of discount less \$	amortization of premium.		
	and Separate Acco	investment expenses and \$ounts.	investment taxes, licenses and fees	s, excluding feder	ral income taxes, attributable to
(h) Includes \$		interest on surplus notes and \$	interest on capital notes.		
(i) Includes \$	0	depreciation on real estate and \$	depreciation on other invested	l assets	

EXHIBIT OF CAPITAL GAINS (LOSSES)

		1	2	3	Δ	5
		'	_	J	7	J
				Total Realized Capital		Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds			(46,844)	0	0
1.1	Bonds exempt from U.S. tax			0		
1.2	Other bonds (unaffiliated)	638,073	0	638,073	237,544	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	0	0	0	0	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans		0	0	0	0
4.	Real estate		0	0		0
5.	Contract loans			0		
6.	Cash, cash equivalents and short-term investments			0		
7.	Derivative instruments			0		
8.	Other invested assets			0	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Total capital gains (losses)	591,229	0	591,229	237,544	0
_	DETAILS OF WRITE-INS	,		,	,	
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from					
3000.	overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9,					
	above)	0	0	0	0	0

EXHIBIT OF NON-ADMITTED ASSETS

		1	2	3 Change in Total
		Current Year Total Nonadmitted Assets	Prior Year Total Nonadmitted Assets	Nonadmitted Assets (Col. 2 - Col. 1)
1.	Bonds (Schedule D)			0
2.	Stocks (Schedule D):			
	2.1 Preferred stocks			0
	2.2 Common stocks			
3.	Mortgage loans on real estate (Schedule B):			
•	3.1 First liens			0
	3.2 Other than first liens			0
4.	Real estate (Schedule A):			
	4.1 Properties occupied by the company			0
	4.2 Properties held for the production of income.			_
	4.3 Properties held for sale			
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)			_
6.	Contract loans			
7.	Derivatives (Schedule DB)			
8.	Other invested assets (Schedule BA)			0
9.	Receivables for securities			_
10.	Securities lending reinvested collateral assets (Schedule DL)			
11.	Aggregate write-ins for invested assets			
12.	Subtotals, cash and invested assets (Lines 1 to 11)			
13.	Title plants (for Title insurers only)			_
14.	Investment income due and accrued			0
15.	Premiums and considerations:			
13.	15.1 Uncollected premiums and agents' balances in the course of collection	1 716 320	1 907 550	101 220
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			
40	15.3 Accrued retrospective premiums and contracts subject to redetermination			0
16.	Reinsurance:			0
	16.1 Amounts recoverable from reinsurers			_
	16.2 Funds held by or deposited with reinsured companies			
	16.3 Other amounts receivable under reinsurance contracts			
	Amounts receivable relating to uninsured plans			
	Current federal and foreign income tax recoverable and interest thereon			
	Net deferred tax asset			
19.	Guaranty funds receivable or on deposit			
20.	Electronic data processing equipment and software			
21.	Furniture and equipment, including health care delivery assets			
22.	Net adjustment in assets and liabilities due to foreign exchange rates			
23.	Receivable from parent, subsidiaries and affiliates			
24.	Health care and other amounts receivable			
25.	Aggregate write-ins for other than invested assets	756,265	3,279,599	2,523,334
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)			
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			
28.	Total (Lines 26 and 27)	14, 193, 169	12,917,995	(1,275,174
1101.	DETAILS OF WRITE-INS			
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501.	Blue Card Program Receivables	104, 168	86,981	(17, 187
2502.	Miscellaneous Receivables		3,485	
2503.	Prepaid Expenses		3, 189, 133	
2598.	Summary of remaining write-ins for Line 25 from overflow page			, ,
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	756,265	3,279,599	

17

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

	EXHIBIT 1 - ENROCEMENT BY I ROBOUT I				<u> </u>		c	
			2	Total Members at End of	4		б Current Year	
	Source of Enrollment	Prior Year	First Quarter	Second Quarter	Third Quarter	5 Current Year	Member Months	
	COMPAND OF ELECTRICAL	1 1101 1 001	i not quartor	Cocona Quantor	Time Quartor	Curront rous	monitor months	
1.	Health Maintenance Organizations	71,963	59, 106	57,276	55,780	54,424	687,051	
2.	Provider Service Organizations							
3.	Preferred Provider Organizations							
4.	Point of Service	1,916	1,930	1,941	1,995	1,461	21,908	
5.	Indemnity Only							
6.	Aggregate write-ins for other lines of business	0	0	0	0	0	0	
7.	Total	73,879	61,036	59,217	57,775	55,885	708,959	
	DETAILS OF WRITE-INS							
0601.								
0602								
0603								
0698.	Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0	
0699	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0	

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying financial statements of Empire HealthChoice HMO, Inc. (the "Company") have been prepared in conformity with the National Association of Insurance Commissioners' ("NAIC") Annual Statement Instructions and in accordance with accounting practices prescribed by the NAIC Accounting Practices and Procedures Manual ("NAIC SAP"), subject to any deviations prescribed or permitted by the New York State Department of Financial Services (the "Department"). The Department has adopted accounting policies found in NAIC SAP as a component of prescribed accounting practices. Additionally, the Department has adopted certain prescribed accounting practices that differ from those found in NAIC SAP, which impact the Company, specifically 1) overdue premiums (in excess of 90 days) from state and local governments or any of its instrumentalities shall be admitted assets; in NAIC SAP, premiums over 90 days due are non-admitted; 2) certain estimated market stabilization reinsurance/pooling recoverables, stop-loss recoverables, and reinsurance recoverables are admitted assets; in NAIC SAP, these recoverables are admitted only upon notification of the refund; and 3) prepaid broker commissions are admitted assets; in NAIC SAP, prepaid broker commissions are nonadmitted assets. The Department has the right to permit other specific practices that deviate from prescribed practices. The Company has employed no permitted practices in preparing the accompanying statutory-basis financial statements.

A reconciliation of the Company's net income (loss) and capital and surplus between NAIC SAP and practices prescribed and permitted by the Department is shown below:

		SSAP#	F/S Page	F/S Line #	2021	2020
Net	Income					
(1)	Empire HealthChoice HMO, Inc. state basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$ (33,487,501)	\$ 10,156,172
(2)	State Prescribed Practices that is an increase/(decrease) from NAIC SAP:					
(3)	State Permitted Practices that is an increase/(decrease) from NAIC SAP:					
(4)	NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$ (33,487,501)	\$ 10,156,172
Sur	<u>plus</u>					
(5)	Empire HealthChoice HMO, Inc. state basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$145,676,610	\$180,201,741
(6)	State Prescribed Practices that is an increase/(decrease) from NAIC SAP:					
	Pooling/Stop Loss recoverable	6	2	25		194,103
	Prepaid Brokers' Commissions	29	2	25	148,336	1,248,377
	Overdue local government premiums	6	2	15.1	339,682	424,689
(7)	State Permitted Practices that is an increase/(decrease) from NAIC SAP:					
(8)	NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$145,188,592	\$178,334,572

B. Use of Estimates in the Preparation of the Financial Statements

Preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

C. Accounting Policies

Health premiums are earned over the term of the related insurance policies and reinsurance contracts. Premiums written are reported net of excess loss reinsurance ceded and experience rating refunds. Unearned premium reserves are established to cover the unexpired portion of premiums written and are computed by pro rata methods for direct business and based on reports received from ceding companies for reinsurance. Premiums paid by subscribers prior to the effective date are recorded on the balance sheet as premiums received in advance and are subsequently credited to income as earned during the coverage period. Premium rates for certain lines of business are subject to approval by the Department. Expenses incurred in connection with acquiring new insurance business, including acquisition costs such as sales commissions, are charged to operations as incurred. All other costs, including underwriting expenses, are charged to operations as incurred.

In addition, the Company uses the following accounting policies:

- (1) Short-term investments include investments with maturities of less than one year and more than three months at the date of acquisition and are reported at amortized cost, which approximates fair value. Non-investment grade short-term investments are stated at the lower of amortized cost or fair value.
- (2) Investment grade bonds not backed by other loans are stated at amortized cost, with amortization calculated based on the modified scientific method, using lower of yield to call or yield to maturity. Non-investment grade bonds are stated at the lower of amortized cost or fair value as determined by various third-party pricing sources.
- (3) The Company has no investments in common stocks of unaffiliated companies.
- (4) The Company has no investments in preferred stocks.
- (5) The Company has no mortgage loans real estate.
- (6) Loan-backed securities are stated at amortized cost. Prepayment assumptions for loan-backed securities and structured securities were obtained from broker-dealer survey values or internal estimates. These assumptions are consistent with the current interest rate and economic environment. The retrospective adjustment method is used to value all loan-backed securities. Non-investment grade loan-backed securities are stated at the lower of amortized cost or fair value.
- (7) The Company has no investments in subsidiaries, controlled and affiliated companies.
- (8) The Company has no investments in joint ventures, partnerships or limited liability companies.
- (9) The Company has no derivative instruments.
- (10) The Company recognizes losses from other-than-temporary impairments ("OTTI") of investments in accordance with Statements of Standard Accounting Practice ("SSAP") No. 26R, *Bonds*; and SSAP No. 30, *Common Stock*; and SSAP No. 32R, *Preferred Stock*.
- (11) The Company does not anticipate investment income as a factor in premium deficiency calculations.
- (12) Unpaid claims and claims adjustment expenses include management's best estimate of amounts based on historical claim development patterns and certain individual case estimates. The established liability considers health benefit provisions, business practices, economic conditions and other factors that may materially affect the cost, frequency and severity of claims. Liabilities for unpaid claims and claim adjustment expenses are based on assumptions and estimates, and while

management believes such estimates are reasonable, the ultimate liability may be in excess of or less than the amount provided. The methods for making such estimates and for establishing the resulting liabilities are continually reviewed and changes in estimates are incorporated into current period estimates.

- (13) The Company has not modified its capitalization policy from the prior period.
- (14) Pharmacy rebate receivables are recorded when earned based upon actual rebate receivables billed and an estimate of receivables based upon current utilization of specific pharmaceuticals and provider contract terms.

D. Going Concern

Not applicable.

2. Accounting Changes and Corrections of Errors

There were no accounting changes or corrections of errors during the years ended December 31, 2021 and 2020.

3. Business Combinations and Goodwill

A. Statutory Purchase Method

Not applicable.

B. Statutory Merger

Not applicable.

C. Assumption Reinsurance

Not applicable.

D. Impairment Loss

Not applicable.

E. Subcomponents and Calculation of Adjusted Surplus and Total Admitted Goodwill

Not applicable.

4. Discontinued Operations

The Company had no operations that were discontinued during 2021 or 2020.

5. Investments

A. Mortgage Loans, including Mezzanine Real Estate Loans

The Company did not have investments in mortgage loans at December 31, 2021 or 2020.

B. Debt Restructuring

The Company did not have invested assets that were restructured debt at December 31, 2021 or 2020.

C. Reverse Mortgages

The Company did not have investments in reverse mortgages at December 31, 2021 or 2020.

D. Loan-Backed Securities

- (1) Prepayment assumptions for single-class and multi-class mortgage-backed and asset-backed securities were obtained from broker-dealer survey values or internal estimates. The Company used various third-party pricing sources in determining the market value of its loan-backed securities.
- (2) The Company did not recognize OTTI on its loan-backed securities during the years ended December 31, 2021 and 2020.
- (3) The Company did not recognize OTTI on its loan-backed securities at December 31, 2021 and 2020.
- (4) All impaired securities (fair value is less than cost or amortized cost) for which an other-than-temporary impairment has not been recognized in earnings as a realized loss (including securities with a recognized other-than-temporary impairment for non-interest related declines when a non-recognized interest related impairment remains):
 - a. The aggregate amount of unrealized losses:

 1. Less than 12 Months \$ (1,053,212)
 2. 12 Months or Longer \$ (210,340)

 b. The aggregate related fair value of securities with unrealized losses:

Less than 12 Months \$ 79,090,327
 12 Months or Longer \$ 4,027,513

(5) The Company's bond portfolio is sensitive to interest rate fluctuations, which impact the fair value of individual securities. Unrealized losses on bonds were primarily caused by the effects of the interest rate environment and the widening of credit spreads on certain securities. The Company currently has the ability and intent to hold these securities until their full cost can be recovered. Therefore, the Company does not believe the unrealized losses represent an OTTI at December 31, 2021 or 2020.

E. Dollar Repurchase Agreements and/or Securities Lending Transactions

- (1) The Company did not enter into repurchase agreements at December 31, 2021 or 2020.
- (2) The Company participates in a securities lending program whereby marketable securities in its investment portfolio are transferred to independent brokers or dealers based on, among other things, their creditworthiness in exchange for collateral initially equal to at least 102% of the market value of the loaned securities. The Company receives the collateral in cash or securities, and if cash is received the cash collateral is thereafter invested according to guidelines of the Company's Investment Policy.

(3) Collateral Received

a. Aggregate amount collateral received

	<u>.</u>	<u>Fair Value</u>
curities Lending		
Open	\$	14,392,182
30 days or less		
31 to 60 days		_
61 to 90 days		_
Greater than 90 days		
Sub-total	\$	14,392,182
Securities received		788,649
Total collateral received	\$	15,180,831
	30 days or less 31 to 60 days 61 to 90 days Greater than 90 days Sub-total Securities received	courities Lending Open 30 days or less 31 to 60 days 61 to 90 days Greater than 90 days Sub-total Securities received

- 2. Dollar repurchase agreement Not applicable.
- b. The fair value of that collateral and of the portion of that collateral that it has sold or repledged \$\\$15,180,831\$
- c. The Company receives cash collateral in an amount in excess of fair value of the securities lent. The Company reinvests the cash collateral according to guidelines of the Company's Investment Policy.
- (4) The Company does not have any securities lending transactions administered by an affiliated agent.

(5) Collateral Reinvestment

Aggregate amount collateral reinvested

			<u>A</u>	mortized Cost	Fair Value
1.	Secu	rities Lending			
	(a)	Open	\$		\$ _
	(b)	30 days or less		4,781,385	4,781,399
	(c)	31 to 60 days		5,794,095	5,794,109
	(d)	61 to 90 days		1,612,479	1,612,662
	(e)	91 to 120 days		1,343,969	1,343,958
	(f)	121 to 180 days		283,941	283,948
	(g)	181 to 365 days		576,106	576,106
	(h)	1 to 2 years			
	(i)	2 to 3 years			
	(j)	Greater than 3 years			<u> </u>
	(k)	Sub-total	\$	14,391,975	\$ 14,392,182
	(1)	Securities received		788,649	788,649
	(m)	Total collateral reinvested	\$	15,180,624	\$ 15,180,831

- 2. Dollar repurchase agreement Not applicable.
- b. Not applicable.
- (6) Not applicable.
- (7) Not applicable.

F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

The Company did not enter into repurchase agreement transactions accounted for as secured borrowing at December 31, 2021 or 2020.

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

The Company did not enter into reverse repurchase agreement transactions accounted for as a secured borrowing at December 31, 2021 or 2020.

H. Repurchase Agreements Transactions Accounted for as a Sale

The Company did not enter into repurchase agreement transactions accounted for as a sale at December 31, 2021 or 2020.

I. Reverse Repurchase Agreements Transactions Accounted for as a Sale

The Company did not enter into reverse repurchase agreement transactions accounted for as a sale at December 31, 2021 or 2020.

J. Real Estate

The Company did not have investments in real estate and did not engage in retail land sales operations during 2021 or 2020.

K. Investments in Low-Income Housing Tax Credits

The Company did not invest in properties generating low-income housing tax credits during 2021 or 2020.

L. Restricted Assets

(1) Restricted assets (including pledged)

		1	2	3	4	5	6	7
Res	stricted Asset Category	Total Gross (Admitted & Nonadmitted) Restricted from Current Year	Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	Increase/ (Decrease) (1 minus 2)	Total Current Year Nonadmitted Restricted	Total Current Year Admitted Restricted (1 minus 4)	Gross Admitted and Nonadmitted Restricted to Total Assets (a)	Admitted Restricted to Total Admitted Assets (b)
a.	Subject to contractual obligation for which liability is not shown	\$ —	\$ —	\$ —	s —	\$ —		
b.	Collateral held under security lending agreements	15,180,624	10,382,589	4,798,035	_	15,180,624	3.41 %	3.52 %
c.	Subject to repurchase agreements	_	_	_	_	_		
d.	Subject to reverse repurchase agreements	_	_	_	_	_		
e.	Subject to dollar repurchase agreements	_	_	_	_	_		
f.	Subject to dollar reverse repurchase agreements	_	_	_	_	_		
g.	Placed under option contracts	_	_	_	_	_		
h.	Letter stock or securities restricted as to sale-excluding FHLB capital stock	_	_	_	_	_		
i.	FHLB capital stock	_	_		_	_		
j.	On deposit with states	55,121,503	56,351,118	(1,229,615)	_	55,121,503	12.38 %	12.79 %
k.	On deposit with other regulatory bodies	_	_	_	_	_		
1.	Pledged as collateral to FHLB (including assets backing funding agreements)	_	_	_	_	_		
m.	Pledged as collateral not captured in other categories	_	_	_	_	_		
n.	Other restricted assets							
0.	Total Restricted Assets	\$ 70,302,127	\$ 66,733,707	\$ 3,568,420	\$ —	\$ 70,302,127	15.79 %	16.31 %

⁽a) Column 1 divided by Asset Page, Column 1, Line 28

- (2) Not applicable.
- (3) Not applicable.

⁽b) Column 5 divided by Asset Page, Column 3, Line 28

(4) Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements

		1	2	3	4
	Collateral Assets	Book/ Adjusted Carrying Value (BACV)	Fair Value	% of BACV to Total Assets (Admitted and Nonadmitted *)	% of BACV to Total Admitted Assets **
a.	Cash	\$ _	\$ _	— %	— %
b.	Schedule D, Part 1	_	_	_	
c.	Schedule D, Part 2 Section 1	_	_	_	
d.	Schedule D, Part 2 Section 2	_	_	_	
e.	Schedule B	_	_	_	
f.	Schedule A	_	_	_	
g.	Schedule BA, Part 1	_	_	_	
h.	Schedule DL, Part 1	15,180,624	15,180,831	3.41 %	3.52 %
i.	Other		_	<u> </u>	<u> </u>
j.	Total Collateral Assets (a+b+c+d+e+f+g+h+i)	\$ 15,180,624	\$ 15,180,831	3.41 %	3.52 %

^{*} Column 1 divided by Asset Page, Line 26 (Column 1)

^{**} Column 1 divided by Asset Page, Line 26 (Column 3)

		<u>1</u>	<u>2</u>
			% of Liability to Total
		Amount	<u>Liabilities</u> *
k.	Recognized Obligation to Return Collateral Asset	\$ 15,180,624	5.32 %

^{*} Column 1 divided by Liability Page, Line 24 (Column 3)

M. Working Capital Finance Investments

The Company did not have any working capital finance investments at December 31, 2021 and 2020.

N. Offsetting and Netting of Assets and Liabilities

The Company did not have any offsetting or netting of assets and liabilities at December 31, 2021 and 2020.

O. 5GI Securities

The Company has no 5GI Securities as of December 31, 2021 and 2020.

P. Short Sales

The Company did not have any short sales at December 31, 2021 and 2020.

Q. Prepayment Penalty and Acceleration Fees

	G	eneral Account
(1) Number of CUSIPs		5
(2) Aggregate Amount of Investment Income	\$	498,449

R. Reporting Entity's Share of Cash Pool by Asset Type

The Company did not participate in a cash pool at December 31, 2021.

6. Joint Ventures, Partnerships and Limited Liability Companies

- **A.** The Company has no investments in joint ventures, partnerships or LLCs.
- **B.** Not applicable.

7. Investment Income

- **A.** All investment income due and accrued with amounts that are over 90 days past due is non-admitted.
- **B.** At December 31, 2021 and 2020 there was no nonadmitted accrued investment income.

8. Derivative Instruments

The Company has no derivative instruments.

9. Income Taxes

A. The components of net deferred tax assets (liabilities):

(1) The components of net deferred tax asset (liabilities) are as follows:

		12/31/2021		
		(1)	(2)	(3)
		Ordinary	Capital	(Col 1+2) Total
(a)	Gross Deferred Tax Assets	\$ 4,061,024	\$ 28,462	\$ 4,089,486
(b)	Statutory Valuation Allowance Adjustments	4,052,809	28,462	4,081,271
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)	8,215	_	8,215
(d)	Deferred Tax Assets Nonadmitted	_	_	_
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	8,215	_	8,215
(f)	Deferred Tax Liabilities	8,215	_	8,215
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$	\$	\$
			12/21/2020	
		(4)	12/31/2020	(6)
		(4)	(5)	(6)
		Ordinary	Capital	(Col 4+5) Total
(a)	Gross Deferred Tax Assets	\$ 7,074,863	\$ 104,043	\$ 7,178,906
(b)	Statutory Valuation Allowance Adjustments	7,068,160	104,045	7,172,205
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)	6,703	(2)	6,701
(d)	Deferred Tax Assets Nonadmitted			
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	6,703	(2)	6,701
(f)	Deferred Tax Liabilities	6,701	_	6,701
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$ 2	\$ (2)	\$ <u> </u>
			Change	
		(7)	(8)	(9)
		(Col 1-4) Ordinary	(Col 2-5) Capital	(Col 7+8) Total
(a)	Gross Deferred Tax Assets	\$ (3,013,839)	\$ (75,581)	\$ (3,089,420)
(b)	Statutory Valuation Allowance Adjustments	(3,015,351)		(3,090,934)
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)	1,512	2	1,514
(d)	Deferred Tax Assets Nonadmitted	_	_	_
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	1,512	2	1,514
(f)	Deferred Tax Liabilities	1,514	_	1,514
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$ (2)	\$ 2	

(2) The amount of admitted adjusted gross deferred tax assets under each component of SSAP No. 101, *Income Taxes* ("SSAP No. 101") are as follows:

			12/31/2021	
		(1)	(2)	(3)
		Ordinary	Capital	(Col 1+2) Total
Adr	mission Calculation Components SSAP No. 101			
(a)	Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.	\$ —	\$ —	\$ —
(b)	Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) 1. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.	_	_	_
	2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.	XXX	XXX	21,851,491
(c)	Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.	8,215	_	8,215
(d)	Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total $(2(a) + 2(b) + 2(c))$	\$ 8,215	\$ —	\$ 8,215
			12/31/2020	
		(4)	(5)	(6)
		Ordinary	Capital	(Col 4+5) Total
Adr	mission Calculation Components SSAP No. 101			
(a)	Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.	\$ —	\$ —	\$ —
(b)	Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)	_	_	_
	 Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. 	_	_	_
	Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.	XXX	XXX	27,030,261
(c)	Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.	6,703	(2)	6,701
(d)	Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total $(2(a) + 2(b) + 2(c))$	\$ 6,703	\$ (2)	\$ 6,701
			Change	
		(7)	(8)	(9)
		(Col 1-4) Ordinary	(Col 2-5) Capital	(Col 7+8) Total
Adr	mission Calculation Components SSAP No. 101			
(a)	Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.	\$ —	\$ —	\$ —
(b)	Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)	_	_	_
	1 Adinated Common Deformed Terr Assets France (ATE D)			

XXX

1,512

1,512 \$

XXX

2

2 \$

(5,178,770)

1,514

1,514

1. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.

Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.

(c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by

(d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))

Gross Deferred Tax Liabilities.

(3)						2021	2	2020
	(a)	Ratio Percentage Used To De Threshold Limitation Amoun		overy Period A	And	498.64	%	537.05 %
	(b)	Amount Of Adjusted Capital Determine Recovery Period 2 2(b)2 Above.			n _\$	145,676,610	\$ 18	30,201,741
(4)			12/31	/2021	12/31	/2020	Ch	ange
			(1)	(2)	(3)	(4)	(5)	(6)
			Ordinary	Capital	Ordinary	Capital	(Col 1-3) Ordinary	(Col 2-4) Capital
	Impa	act of Tax-Planning Strategies						
		Determination of Adjusted Gross Deferred Tax Assets and Net Admitted Deferred Tax Assets, By Tax Character As A Percentage.						
		1. Adjusted Gross DTAs Amount From Note 9A1(c)	\$ 8,215	\$ —	\$ 6,703	\$ (2)	\$ 1,512	\$ 2
		2. Percentage of Adjusted Gross DTAs By Tax Character Attributable To The Impact Of Tax Planning Strategies	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %
		3. Net Admitted Adjusted Gross DTAs Amount From Note 9A1(e)	\$ 8,215	\$ —	\$ 6,703	\$ (2)	\$ 1,512	\$ 2
		4. Percentage of Net Admitted Adjusted Gross DTAs By Tax Character Admitted Because Of The Impact Of Tax Planning Strategies	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %
	(b)	Does the Company's tax-plant use of reinsurance?	ning strategies	s include the	Yes		No	X
В.	The 202	e Company has no un 20.	recognize	d deferre	l tax liabi	lities at D	ecember	31, 2021 ar
C.	Cu	rrent income taxes inc	curred cor	isist of th	e followin	g major c	omponen	its:
					(1)	(2)		(3)
					12/31/2021	12/31/2		(Col 1-2) Change
(1)	Cur	rent Income Tax		L				8.

			12/31/2021	12/31/2020	Change	
)	Cur	rent Income Tax				
	(a)	Federal	\$ (13,964,485)	\$ (2,379,942) \$	(11,584,	543)
	(b)	Foreign	_	_		
	(c)	Subtotal	(13,964,485)	(2,379,942)	(11,584,	543)
	(d)	Federal income tax expense on net capital gains	223,747	634,891	(411,	144)
	(e)	Utilization of capital loss carry-forwards	_	_		_
	(f)	Other	_	_		
	(g)	Federal and foreign income taxes incurred	\$ (13,740,738)	\$ (1,745,051) \$	(11,995,	687)

				(1)	(2)	(3)
				12/31/2021	12/31/2020	(Col 1-2) Change
(2)	Def	erred T	ax Assets:			
	(a)	Ordin	ary			
		(1)	Discounting of unpaid losses	\$ 235,534	\$ 374,770	\$ (139,236)
		(2)	Unearned premium reserve	24,272	20,185	4,087
		(3)	Policyholder reserves	504,000	609,772	(105,772)
		(4)	Investments	_	_	_
		(5)	Deferred acquisition costs	_	_	_
		(6)	Policyholder dividends accrual	_	_	_
		(7)	Fixed assets	_	_	_
		(8)	Compensation and benefits accrual	_	_	_
		(9)	Pension accrual	_	_	_
		(10)	Receivables - nonadmitted	2,851,591	2,006,863	844,728
		(11)	Net operating loss carry-forward	_	_	_
		(12)	Tax credit carry-forward	_	_	_
		(13)	Other (including items <5% of total ordinary	(0.0(7	12.255	49.612
		(1.4)	tax assets)	60,967	12,355	48,612
		(14)	Accrued future expenses	32,777	84,293	(51,516)
		(15)	Premium deficiency reserves	251 002	3,704,546	(3,704,546)
		(16)	Prepaid expenses (99) Subtotal	351,883	262,079	89,804
	(1-)	Ctatas		4,061,024	7,074,863	(3,013,839)
	(b) (c)		tory valuation allowance adjustment dmitted	4,052,809	7,068,160	(3,015,351)
	(d)	Admi	tted ordinary deferred tax assets (2a99 - 2b - 2c)	8,215	6,703	1,512
	(e)	Capit	al			
		(1)	Investments	28,462	104,043	(75,581)
		(2)	Net capital loss carry-forward	_	_	_
		(3)	Real estate	_	_	_
		(4)	Other (including items <5% of total capital tax assets)	_	_	_
			(99) Subtotal	28,462	104,043	(75,581)
	(f)	Statut	tory valuation allowance adjustment	28,462	104,045	(75,583)
	(g)	Nona	dmitted		_	_
	(h)	Admi	tted capital deferred tax assets (2e99 - 2f - 2g)	_	(2)	2
	(i)	Admi	tted deferred tax assets (2d + 2h)	\$ 8,215	\$ 6,701	\$ 1,514
(3)	Def	erred T	ax Liabilities:			
. ,	(a)	Ordin				
		(1)	Investments	\$ —	\$ —	s —
		(2)	Fixed assets	_	_	_
		(3)	Deferred and uncollected premium	_	_	_
		(4)	Policyholder reserves	_	_	_
		(5)	Other (including items <5% of total ordinary tax liabilities)	_	_	_
		(6)	Discount of coordination of benefits	8,215	6,701	1,514
			(99) Subtotal	8,215	6,701	1,514
	(b)	Capit	al			
		(1)	Investments	_	_	_
		(2)	Real estate	_	_	_
		(3)	Other (including items <5% of total capital tax liabilities)	_	_	_
			(99) Subtotal		_	_
	(c)	Defer	red tax liabilities (3a99 + 3b99)	\$ 8,215	\$ 6,701	\$ 1,514
			ed tax assets/liabilities (2i - 3c)	<u> </u>	\$ —	s —
(4)	INCL	acterr				Ψ

D. The Company's income tax expense and change in deferred income taxes differs from the amount obtained by applying the federal statutory income tax rate of 21% for the year ended December 31 as follows:

	2021	2020
Tax expense computed using federal statutory rate	\$ (9,917,930) \$	1,766,335
ACA health insurer fee	_	3,543,167
Change in nonadmitted assets	(267,787)	2,753,569
Tax exempt income and dividend received deduction net of proration	(516,225)	(547,132)
Prior year true-up and adjustments	9	_
Valuation allowance	(3,090,935)	(9,215,143)
Other, net	 2,246	865
Total	\$ (13,790,622) \$	(1,698,339)
Federal income taxes incurred	(13,740,738) \$	(1,745,051)
Change in net deferred income taxes	 (49,884)	46,712
Total statutory income taxes	\$ (13,790,622) \$	(1,698,339)

E. Operating loss carryforwards:

- (1) The Company has no operating loss carryforwards and no tax credit carryforwards as of December 31, 2021 or 2020.
- (2) The Company has no federal income taxes available for recoupment.
- (3) The Company has no protective tax deposits reported as admitted assets under Section 6603 of the Internal Revenue Service Code as of December 31, 2021 and 2020.
- **F.** The following companies will be included in the consolidated federal income tax return with their parent Anthem, Inc. ("Anthem") as of December 31, 2021 and either are current members of the consolidated tax sharing agreement or are in the process of being added to the consolidated tax sharing agreement. Allocation of federal income taxes with affiliates subject to the tax sharing agreement is based upon separate income tax return calculations with credit for net losses that can be used on a consolidated basis. Pursuant to this agreement, the Company has the enforceable right to recoup federal income taxes paid in prior years in the event of future losses, which it may incur, or to recoup its net losses carried forward as an offset to future net income subject to federal income taxes. Intercompany income tax balances are settled based on the Internal Revenue Service due dates.

Alliance Care Management, LLC Designated Agent Company, Inc.

American Imaging Management, Inc. EHC Benefits Agency, Inc.

America's 1st Choice of South Carolina, Inc.

Empire HealthChoice Assurance, Inc.

America's Health Management Services, Inc.

Empire HealthChoice HMO, Inc.

Empire HealthChoice HMO, Inc.

Federal Government Solutions, LLC

AMERIGROUP Corporation FHC Health Systems, Inc.

Amerigroup Delaware, Inc. Freedom Health, Inc.

Amerigroup District of Columbia, Inc. Golden West Health Plan, Inc.

Amerigroup Health Plan of Louisiana, Inc.

Health Core, Inc.

Amerigroup Insurance Company

Health Management Corporation

AMERIGROUP Iowa, Inc.

AMERIGROUP Maryland, Inc.

Amerigroup Mississippi, Inc.

HealthLink HMO, Inc.

HealthLink, Inc.

AMERIGROUP New Jersey, Inc. HealthLink Insurance Company

AMERIGROUP Ohio, Inc. HealthPlus HP, LLC
Amerigroup Oklahoma, Inc. HealthSun Health Plan, Inc.

Amerigroup Pennsylvania, Inc. Healthy Alliance Life Insurance Company

AMERIGROUP Tennessee, Inc.

AMERIGROUP Texas, Inc.

HEP AP Holdings, Inc.

HMO Colorado, Inc.

HMO Missouri, Inc.

AMGP Georgia Managed Care Company, Inc.

IEC Group Holdings, Inc.

Anthem Blue Cross Life and Health Insurance Company IEC Group, Inc. d/b/a AmeriBen

Anthem Financial, Inc.

Imaging Management Holdings, LLC

Anthem Health Plans of Kentucky, Inc. IngenioRx, Inc.

Anthem Health Plans of Maine, Inc.

Legato Health Technologies U.S., Inc.

Anthem Health Plans of New Hampshire, Inc.

Legato Holdings I, Inc.

Anthem Health Plans of Virginia, Inc.

Living Complete Technologies, Inc.

Anthem Health Plans, Inc.

Massachusetts Behavioral Health Partnership

Anthem Holding Corp. Matthew Thornton Health Plan, Inc.

Anthem Insurance Companies, Inc. Missouri Care, Incorporated

Anthem Kentucky Managed Care Plan, Inc. myNEXUS Holdings, Inc.

Anthem Southeast, Inc. myNEXUS, Inc.

Anthem UM Services, Inc. myNEXUS Management, Inc.

Anthem OW Services, me.

Anthem, Inc.

Nash Holding Company, LLC

Arcus Enterprises, Inc.

Aspire Health, Inc.

Nash Holding Company, LLC

National Government Services, Inc.

New England Research Institutes, Inc.

Associated Group, Inc.

Optimum Healthcare, Inc.

Beacon Health Financing, LLC

OPTIONS Health Care, Inc.

Beacon Health Options Care Services, Inc.

Park Square Holdings, Inc.

Beacon Health Options Holdco, Inc.

Park Square I, Inc.

Park Square II, Inc.

Beacon Health Options, Inc.

Beacon Health Options of California, Inc.

Resolution Health, Inc.

Beacon Health Options of Ohio, Inc. RightCHOICE Managed Care, Inc.

Beacon Health Options of Pennsylvania, Inc.

Rocky Mountain Hospital and Medical Service, Inc.

Beacon Health Vista Parent, Inc. SellCore, Inc.

BHS IPA, LLC Simply Healthcare Plans, Inc.

Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Southeast Services, Inc.

Blue Cross Blue Shield of Wisconsin State Sponsored Services, Inc.
Blue Cross of California The Anthem Companies, Inc.

Blue Cross of California Partnership Plan, Inc.

The Anthem Companies of California, Inc.

CareMarket, Inc. TrustSolutions, LLC

CareMore Health IPA of New York, Inc.

UNICARE Health Plan of West Virginia, Inc.

CareMore Health Plan UNICARE Illinois Services, Inc.

CareMore Health Plan of Arizona, Inc.

UNICARE Life & Health Insurance Company

CareMore Health Plan of Nevada, Inc.

CareMore Health Plan of Texas, Inc.

UNICARE Specialty Services, Inc.

UNICARE Specialty Services, Inc.

Value Health Reinsurance, Inc.

ValueOptions Federal Services, Inc.

CHCS IPA, Inc.

Claim Management Services, Inc.

ValueOptions of Kansas, Inc.

ValueOptions of New Jersey, Inc.

Community Care Health Plan of Kansas, Inc.

ValueOptions Texas, Inc.

Community Care Health Plan of Nebraska, Inc. Valus, Inc.

Community Care Health Plan of Nevada, Inc. WellPoint California Services, Inc.

Community Insurance Company WellPoint Dental Services, Inc.

Compcare Health Services Insurance Corporation WellPoint Health Solutions, Inc.

Crossroads Acquisition Corp. WellPoint Holding Corporation

DBG Holdings, Inc. WellPoint Information Technology Services, Inc.

DeCare Analytics, LLC WellPoint Insurance Services, Inc.

DeCare Dental Health International, LLC WellPoint Military Care Corporation

DeCare Dental Networks, LLC ZipDrug, Inc.

DeCare Dental, LLC

G. Not applicable.

H. Repatriation Transition Tax (RTT)

Not applicable.

I. Alternative Minimum Tax (AMT) Credit

Not applicable.

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

A. Nature of the Relationship

The Company is a New York domiciled stock health maintenance organization ("HMO") and is a wholly-owned subsidiary of Empire HealthChoice Assurance, Inc. ("EHCA"), which is an indirect wholly-owned subsidiary of Anthem, a publicly traded company.

B. Significant Transactions for Each Period

There were no significant transactions during the years ended December 31, 2021 and 2020.

For changes to the intercompany management and service arrangements see Note 10E. The amounts of transactions under such agreements are presented in Schedule Y, Part 2.

C. Transactions with Related Parties who are not Reported on Schedule Y

The Company has no transactions with related parties who are not reported on Schedule Y.

D. Amounts Due to or from Related Parties

At December 31, 2021 and 2020, the Company reported no amounts due from affiliates. At December 31, 2021 and 2020, the Company reported \$139,337,162 and \$59,856,905 due to affiliates, respectively. The receivable and payable balances represent intercompany transactions that will be settled in accordance with the settlement terms of the intercompany agreement.

Following is a summary of transactions between the Company and various affiliates during the years:

	2021		2020
The Anthem Companies, Inc.	 		
Medical Management	\$ 15,364,901	\$	18,720,005
MIS-IT	2,864,816		2,947,883
Sales	5,812,146		11,821,007
Customer Service	4,663,027		5,429,738
Claims	877,391		1,166,096
Provider Network	1,474,335		2,008,514
Enrollment and Billing	743,073		970,869
Operations Support	1,844,000		2,176,051
Finance	515,381		692,383
Decision Support	544,513		615,225
Underwriting	14,293		23,338
Legal and Compliance	648,025		794,899
Human Resources	371,616		445,109
Marketing	1,225,013		1,223,872
General Management	147,453		82,795
Product Development and Management	291,946		346,540
Planning	52,808		50,726

General Administration	187,835	276,945
Other	 911,890	 1,195,497
Total	\$ 38,554,462	\$ 50,987,492
Anthem, Inc.	• • • • • • • • • • • • • • • • • • • •	2 20 6 1 6 6
MIS-IT	\$ 2,980,889	\$ 3,286,166
Medical Management	10,031,409	10,786,099
General Management	826,050	1,091,377
Print Mail	598,171	710,756
Customer Service	2,426,094	2,178,630
Marketing	7,746,361	9,672,373
Legal and Compliance	943,071	2,156,196
Provider Network	435,791	418,551
Sales	9,707,262	10,291,433
Claims	(31,498)	864,954
Enrollment and Billing	265,164	372,378
General Administration	(174,396)	480,292
Finance	87,111	116,791
Product Development & Management	27,846	39,544
Operations Support	7,842,587	7,752,015
External Affairs	109,159	166,770
Decision Support	58,158	100,570
Other	 1,274,681	 853,865
Total	\$ 45,153,910	\$ 51,338,760
WellPoint Information Technology Services, Inc.		
MIS-IT	\$ 1,036,658	\$ 988,540
Other	 830	 1,281
Total	\$ 1,037,488	\$ 989,821
WellPoint Holding Corporation		
Claims	\$ 9	\$ 768
Medical Management	2,914	13,839
Other	 6,003	 10,205
Total	\$ 8,926	\$ 24,812
Costs allocated from other Anthem, Inc. affiliates not listed above		
Medical Management	\$ (5,181,308)	\$ (3,076,210)
General Administration	(193,140)	(564,990)
Provider Network	8,050	684
MIS-IT	102,162	545,630
Finance	30,449	40,707
External Affairs	5,945	2,768
Product Development and Management	5,795	2,034
Claims	561,278	897,494
General Management	68,145	32,753
Decision Support	8,920	5,078
Credentialing	131	330
Marketing	23,175	21,208
Customer Service	1,659	555
Print Mail	350	1,343
Legal and Compliance	3,948	97
Clinical Health Policy	27,429	152
Human Resources	26,255	1,172
Sales	359,944	163,518
Planning	155	418
Actuarial Valuation	388	253
Operations Support	337,398	438,099
Other	1,913	(574,075)
Total	\$ (3,800,959)	\$ (2,060,982)
Net Costs Allocated to the Company	\$ 80,953,827	\$ 101,279,903
Federal Tax Payments to Anthem, Inc.	(9,227,886)	3,743,138
ACA Fee Assessment		16,872,226
Total Schedule Y, Part 2, Column 8	\$ 71,725,941	\$ 121,895,267

E. Management and Service Contracts and Cost Sharing Arrangements

The Company has entered into administrative services agreements with its affiliated companies. Pursuant to these agreements, various administrative, management and support services are provided to or provided by the Company. The costs and expenses related to these administrative management and support services are allocated to or allocated by the Company in an amount equal to the direct and indirect costs and expenses incurred in providing these services. Costs include expenses such as salaries, employee benefits, information technology, pharmacy benefits administration, communications, advertising, consulting services, rent, utilities, billing, accounting, underwriting, and product development, which support the Company's operations. These costs are allocated based on various utilization statistics.

F. Guarantees or Contingencies for Related Parties

The Company did not enter into guarantees or undertakings for the benefit of an affiliate which would result in a material contingent exposure of the Company's or any affiliated insurer's assets or liabilities.

G. Nature of Control Relationships that Could Affect Operations or Financial Position

EHCA owns all outstanding shares of the Company. The Company's ultimate parent is Anthem.

H. Amount Deducted for Investment in Upstream Company

The Company does not own shares of upstream intermediate entities or Anthem.

I. Detail of Investments in Affiliates Greater than 10% of Admitted Assets

At December 31, 2021 and 2020, the Company did not have investments in affiliates.

J. Write-down for Impairments of Investments in Subsidiaries, Controlled or Affiliated ("SCA") Companies

Not applicable.

K. Investment in a Foreign Insurance Subsidiary

The Company does not have investments in foreign insurance subsidiaries.

L. Investment in Downstream Non-insurance Holding Companies

The Company does not have investments in downstream non-insurance holding companies.

M. All SCA Investments

The Company has no SCA Investments.

N. Investment in Insurance SCAs

The Company does not have investments in Insurance SCAs.

O. SCA or SSAP 48 Entity Loss Tracking

The Company does not have losses on investments in Insurance SCAs and/or joint ventures, partnerships or LLCs.

11. Debt

A. Capital Notes and Other Debt

The Company had no capital notes or other debt outstanding at December 31, 2021 and 2020.

B. FHLB (Federal Home Loan Bank) Agreements

The Company had no FHLB agreements outstanding at December 31, 2021 and 2020.

C. All Other Debt

The Company had no other debt outstanding at December 31, 2021 and 2020.

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

A. Defined Benefit Plan

Not applicable - See Note 12G.

- **B.** Not applicable See Note 12G.
- C. Not applicable See Note 12G.
- **D.** Not applicable See Note 12G.

E. Defined Contribution Plans

Not applicable - See Note 12G.

F. Multiemployer Plans

The Company does not participate in a multiemployer plan.

G. Consolidated/Holding Company Plans

The Company participates in frozen non-contributory defined benefit pension plans sponsored by ATH Holding Company, LLC ("ATH Holding"), covering most employees of Anthem and its subsidiaries. ATH Holding allocates a share of the total accumulated costs of the plans to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under these plans.

The Company participates in a postretirement medical benefit plan, sponsored by ATH Holding, providing certain health, life, vision and dental benefits to eligible retirees. ATH Holding allocates a share of the total accumulated costs of this plan to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

The Company participates in a nonqualified deferred compensation plan sponsored by Anthem which covers certain employees once the participant reaches the maximum contribution amount for the Anthem 401(k) Plan (the "401(k) Plan"). The deferred

amounts are payable according to the terms and subject to the conditions of the deferred compensation plan. Anthem allocates a share of the total accumulated costs of this plan to the Company based on the number of allocated employees subject to the deferred compensation plan. The Company has no legal obligation for benefits under this plan.

The Company participates in the 401(k) Plan, sponsored by ATH Holding and covering substantially all employees. Voluntary employee contributions are matched by ATH Holding subject to certain limitations. ATH Holding allocates a share of the total accumulated costs of this plan to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

The Company participates in a stock incentive compensation plan, sponsored by Anthem, providing incentive awards to non-employee directors and employees, consisting of Anthem stock options, restricted stock, restricted stock units, stock appreciation rights, performance shares, and performance units. Anthem allocates a share of the total share-based compensation expense of this plan to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

During 2021 and 2020, the Company was allocated the following costs or (credits) for these retirement benefits:

		2021	2020
Defined benefit pension plan	\$	(107,686) \$	(271,453)
Postretirement medical benefit plan	1	(64,611)	(95,836)
Deferred compensation plan		12,563	17,513
Defined contribution plan		950,863	1,221,052
Stock incentive compensation plan		556,476	695,845

H. Post Employment Benefits and Compensated Absences

Not applicable.

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

Not applicable.

13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations

A. Outstanding Shares

As of December 31, 2021, the Company has 200,000 shares of \$.01 par value common stock authorized, issued and outstanding.

B. Preferred Stock

The Company has no preferred stock outstanding.

C. Dividend Restrictions

Under New York law, the Company is limited in the amount of dividends that can be declared without regulatory approval. The Department and the New York State Department of Health ("NYDOH") must approve any dividend that exceeds the lesser of 10% of its capital and surplus or 100% of adjusted net investment income. Also, any dividend paid from other than positive unassigned surplus shall be considered an extraordinary dividend, and will need approval of the Insurance Commissioner.

D. Dividends Paid

See Footnote 10B.

E. Maximum Ordinary Dividend During 2022

Within the limitations of (C) above, the Company may not pay dividends during 2022 without prior approval.

F. Unassigned Surplus Restrictions

Unassigned surplus funds are not restricted at December 31, 2021.

G. Mutual Surplus Advances

Not applicable.

H. Company Stock Held for Special Purpose

There are no shares of stock held for special purposes at December 31, 2021.

I. Changes in Special Surplus Funds

There are no special surplus funds at December 31, 2021.

J. Changes in Unassigned Funds

The portion of unassigned funds represented by cumulative unrealized investment gains and losses was \$(21,234) at December 31, 2021.

K. Surplus Notes

The Company has not issued any surplus notes or debentures or similar obligations.

L. Restatement due to Prior Quasi-reorganizations

The Company had no restatements due to prior quasi-reorganizations.

M. Quasi-reorganizations over Prior 10 Years

The Company has not been involved in a quasi-reorganization during the past 10 years.

14. Liabilities, Contingencies and Assessments

A. Contingent Commitments

The Company had no contingent commitments at December 31, 2021 or 2020.

B. Assessments

New York does not have an insolvency or guaranty association law under which the Company can be assessed for amounts paid by guaranty funds for member losses when a health insurance company or HMO becomes insolvent.

The Company participates in risk sharing pools, including the Demographic and Specified Medical Conditions (Regulation 164) and Stop Loss (Regulation 171) pools. These pools are intended to subsidize health insurance carriers for unfavorable claims experience. The Company is also subject to Bad Debt and Charity Care pools which

subsidize financially stressed hospitals and Graduate Medical Expenses ("GME") assessments which subsidize hospital indigent care and health care initiatives.

C. Gain Contingencies

The Company has no gain contingencies at December 31, 2021 or 2020.

D. Claims-Related Extra Contractual Obligation and the Bad Faith Losses Stemming From Lawsuits

Not applicable.

E. Joint and Several Liabilities

Not applicable.

F. All Other Contingencies

Litigation and regulatory proceedings

Blue Cross Blue Shield Antitrust Litigation

Anthem Inc. ("Anthem") is a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees ("Blue Plans") across the country. Cases filed in twenty-eight states were consolidated into a single, multi-district proceeding captioned *In re Blue Cross Blue Shield Antitrust Litigation* that is pending in the United States District Court for the Northern District of Alabama (the "Court"). Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard® and National Accounts program and other arrangements in violation of the Sherman Antitrust Act ("Sherman Act"), and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.

In April 2018, the Court issued an order on the parties' cross motions for partial judgment, determining that the defendants' aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard® program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. The Court also found that there remain genuine issues of material fact as to whether defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks. In April 2019, plaintiffs filed motions for class certification, which defendants opposed.

The BCBSA and Blue plans have approved a settlement agreement and release (the "Subscriber Settlement Agreement"), with the subscriber plaintiffs. If approved by the Court, the Subscriber Settlement Agreement will require defendants to make a monetary settlement payment, Anthem's portion of which is estimated to be \$594,000,000 and will contain certain non-monetary terms including (i) eliminating the "national best efforts" rule in the BSBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan. As of December 31, 2021, the liability balance accrued for Anthem's estimated payment obligation was \$507,000,000, net of payments made. The Company recorded its estimated portion of the Subscriber Settlement Agreement, net of third party insurance coverage, in 2020.

In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. All terms of the Subscriber Settlement Agreement are subject to final approval by the Court. The deadlines for objections to the settlement as well as the deadline for those who wish to opt-out from the settlement was in July 2021 and a small number of subscribers submitted valid opt outs by the deadline. The claims deadline was in November 2021 and an excess of eight thousand claims were submitted. A final approval hearing was held in October 2021. The Court took the request for approval under advisement and requested supplemental briefing that has been submitted. If the Court grants approval of the Subscriber Settlement Agreement, and after all appellate rights have expired or have been exhausted in a manner that affirms the Court's final order and judgement, the defendants' payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective.

In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determines the standard of review applicable to the providers' claims. In May 2021, the defendants and provider plaintiffs filed renewed standard of review motions which are now fully briefed. In June 2021, the parties filed summary judgment motions not critically dependent on class certification which are now fully briefed. No decision has been rendered. Anthem intends to continue to vigorously defend the provider suit, which they believe is without merit; however, its ultimate outcome cannot be presently determined.

Express Scripts, Inc. Pharmacy Benefit Management Litigation

In March 2016, Anthem filed a lawsuit against Express Scripts, Inc. ("Express Scripts"), their vendor at the time for PBM services, captioned *Anthem, Inc. v. Express Scripts, Inc.*, in the U.S. District Court for the Southern District of New York. The lawsuit seeks to recover over \$14,800,000,000 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the "ESI PBM Agreement"), over \$158,000,000 in damages related to operational breaches, as well as various declarations under the ESI PBM Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to Anthem through the term of the ESI PBM Agreement; (iii) has breached the ESI PBM Agreement; and (iv) is required under the ESI PBM Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination.

Express Scripts has disputed Anthem's contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI PBM Agreement, and (ii) that it has no obligation to ensure that Anthem receives any specific level of pricing, that Anthem has no contractual right to any change in pricing under the ESI PBM Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that Anthem has been unjustly enriched by its payment of \$4,675,000,000 at the time they entered into the ESI PBM Agreement. In March 2017, the court granted Anthem's motion to dismiss Express Scripts' counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. The only remaining claims are for breach of contract and declaratory relief. In August 2021, ESI filed a motion for summary judgment, which Anthem opposed. Express Scripts' motion for summary judgment is now fully briefed and no decision has been rendered. Anthem intends to vigorously pursue their claims and defend against any counterclaims, which they believe are without merit; however, the ultimate outcome cannot be presently determined.

In re Express Scripts/Anthem ERISA Litigation

Anthem is a defendant in a class action lawsuit that was initially filed in June 2016 against Anthem, Inc. and Express Scripts, which has been consolidated into a single multi-district lawsuit captioned In Re Express Scripts/Anthem ERISA Litigation, in the U.S. District Court for the Southern District of New York. The consolidated complaint was filed by plaintiffs against Express Scripts and Anthem on behalf of all persons who are participants in or beneficiaries of any ERISA or non-ERISA healthcare plan from December 1, 2009 to December 31, 2019 in which Anthem provided prescription drug benefits through the ESI PBM Agreement and paid a percentage based co-insurance payment in the course of using that prescription drug benefit. The plaintiffs allege that Anthem breached their duties, either under ERISA or with respect to the implied covenant of good faith and fair dealing implied in the health plans, (i) by failing to adequately monitor Express Scripts' pricing under the ESI PBM Agreement, (ii) by placing their own pecuniary interest above the best interests of their insureds by allegedly agreeing to higher pricing in the ESI PBM Agreement in exchange for the purchase price for their NextRx PBM business, and (iii) with respect to the non-ERISA members, by negotiating and entering into the ESI PBM Agreement that was allegedly detrimental to the interests of such non-ERISA members. Plaintiffs seek to hold Anthem and Express Scripts jointly and severally liable and to recover all losses suffered by the proposed class, equitable relief, disgorgement of alleged ill-gotten gains, injunctive relief, attorney's fees and costs and interest.

In April 2017, Anthem filed a motion to dismiss the claims brought against them, and it was granted, without prejudice, in January 2018. Plaintiffs filed a notice of appeal with the United States Court of Appeals for the Second Circuit (the "Second Circuit"), which was heard in October 2018. In December 2020, the Court affirmed the trial court's decision dismissing the ERISA complaint. Plaintiffs filed a Petition for Rehearing and Rehearing En Banc, which was denied. Plaintiffs filed a writ of certiorari with the United States Supreme Court, which Anthem opposed, and the plaintiffs have replied. In December 2021, the United States Supreme Court requested that the Solicitor General submit a brief "expressing the views of the United States" as to whether the Court should grant plaintiffs' writ. Anthem intends to vigorously defend this suit, which they believe is without merit; however, its ultimate outcome cannot be presently determined.

Medicare Risk Adjustment Litigation

In March 2020, the U.S. Department of Justice ("DOJ") filed a civil lawsuit against Anthem, Inc. in the U.S. District Court for the Southern District of New York in a case captioned *United States v. Anthem, Inc.* The DOJ's suit alleges, among other things, that Anthem falsely certified the accuracy of the diagnosis data they submitted to the Centers for Medicare and Medicaid Services ("CMS") for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, Anthem caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled Anthem to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its allegations. In September 2020, Anthem filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint. The motions are fully briefed and no decision has been rendered. Anthem intends to continue to vigorously defend this suit, which they believe is without merit; however, the ultimate outcome cannot be presently determined.

Other Contingencies

From time to time, the Company is party to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. The

Company, like HMOs and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, PPO, and other plans. The Company is, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on the Company. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.

In addition to the lawsuits described above, the Company is also involved in other pending and threatened litigation of the character incidental to their business, and is from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on the Company's business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on the Company's financial position or results of operations.

The Company has no other known material contingencies.

Provisions for uncollectible amounts

At December 31, 2021 and 2020, the Company reported admitted assets of \$9,241,155 and \$6,111,154 respectively, in premium receivables and receivables due from uninsured plans. Based upon the Company's experience, any uncollectible receivables are not expected to exceed \$1,829,852 that was nonadmitted at December 31, 2021; therefore, no additional provision for uncollectible amounts has been recorded. The potential for any additional loss is not believed to be material to the Company's financial condition.

15. Leases

A. Lessee Operating Lease

- (1) The Company leases office space, office equipment, EDP equipment, and software under various noncancelable operating leases. Certain leases have the right to renew. There are no escalation clauses for any lease. Related lease expense for 2021 and 2020 was \$1,020,535 and \$1,281,434, respectively.
- (2) At December 31, 2021, the minimum aggregate rental commitments are as follows:

	Year Ending December 31	(Operating Leases
1	2022	\$	688,620
2	2023		709,279
3	2024		730,561
4	2025		370,682
5	2026		_
6	Total	\$	2,499,142

(3) The Company has not entered into any material sale-leaseback transactions.

B. Lessor Leases

(1) The Company has not entered into any operating leases.

(2) The Company has not entered into any leveraged leases.

16. Information About Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk

The Company has no significant financial instruments with off-balance sheet risk.

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of investment securities. All investment securities are managed by professional investment managers within policies authorized by the board of directors. Such policies limit the amounts that may be invested in any one issuer and prescribe certain investee company criteria. As of December 31, 2021, there were no significant concentrations.

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

Not applicable at December 31, 2021 and 2020.

B. Transfer and Servicing of Financial Assets

- (1) The Company participates in a securities lending program whereby marketable securities in its investment portfolio are transferred to independent brokers or dealers. At December 31, 2021 the fair value of securities loaned was \$14,863,656 and the carrying value of securities loaned was \$14,054,312.
- (2) (7) Not applicable.

C. Wash Sales

- (1) In the course of the Company's asset management, securities may be sold and reacquired within 30 days of the sale date to enhance the yield on the investments.
- (2) At December 31, 2021 and 2020, there were no wash sales involving securities with an NAIC designation of 3 or below or unrated.

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

A. Administrative Services Only ("ASO") Plans

Not applicable at December 31, 2021.

B. Administrative Services Contract ("ASC") Plans

Not applicable at December 31, 2021.

C. Medicare or Other Similarly Structured Cost-Based Reimbursement Contract

(1) The Company does not record revenue explicitly attributable to the cost share and reinsurance components of administered Medicare products.

(2)	Receivable from	Related to	2021	2020		
	Centers for Medicare and Medicaid Services	Cost share and reinsurance components of administered Medicare products	\$ 24,997,827	\$ 19,775,377		
	U.S. Department of Health and Human Services	Cost share and reinsurance components of administered commercial ACA products	\$ — 5	\$ _		
	Uninsured plans	Uninsured business, not including pharmaceutical rebate receivables	\$ _ 5	\$ _		

- (3) As no revenue is recorded in connection with the cost share and reinsurance components of the Company's Medicare and ACA products, the Company has recorded no allowances and reserves for the adjustment of recorded revenues and receivables.
- (4) The Company has made no adjustment to revenue resulting from the audit of cost-reimbursement receivables related to revenues recorded in the prior period.

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

No premiums were written by managing general agents or third party administrators during the years ended December 31, 2021 and 2020.

20. Fair Value Measurements

A.

(1) Fair Value Measurements at Reporting Date:

Description for each class of asset or liability	(Leve	11)	П	Level 2)	а	Level 3)	N	Net Asset Value (NAV)	Total
a. Assets at fair value	(====)	(-		(-			(4.52.7)	
Bonds									
Industrial and misc	\$	_	\$ 1	,173,731	\$	_	\$	— \$	1,173,731
Total bonds	\$	_	\$ 1	,173,731	\$	_	\$	— \$	1,173,731
Total assets at fair value/NAV	\$		\$ 1	,173,731	\$		\$		1,173,731

(2) Fair Value Measurements in (Level 3) of the Fair Value Hierarchy

There are no investments in Level 3 as of December 31, 2021 and 2020.

- (3) The Company's policy is to recognize transfers between Levels, if any, as of the beginning of the reporting period.
- (4) Fair values of bonds are based on quoted market prices, where available. These fair values are obtained primarily from third party pricing services, which generally use Level 1 or Level 2 inputs, for the determination of fair value to facilitate fair value measurements and disclosures. Level 2 securities primarily include United States government securities, corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. The Company has controls in place to review the pricing services' qualifications and procedures used to determine fair values. In addition, the Company

periodically reviews the pricing services' pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable.

Certain bonds, primarily corporate debt securities, are designated Level 3. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.

There have been no significant changes in the valuation techniques during the current period.

B. Fair Value Measurements Under Other Accounting Pronouncements

Not applicable at December 31, 2021 and 2020.

C. Financial Instruments

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Practicable (Carrying Value)
Bonds	\$331,023,457	\$320,250,647	\$ —	\$331,023,457	\$ —	\$ —	\$
Securities lending collateral asset	15,180,831	15,180,624	_	15,180,831	_	_	_

D. Not Practicable to Estimate Fair Value

There are no financial instruments that were not practicable to estimate fair value.

E. Investments Measured at Net Asset Value

The Company has no investments measured at net asset value.

21. Other Items

A. Unusual or Infrequent Items

The spread of the COVID-19 virus caused significant financial market volatility, economic uncertainty, and interruptions to normal business activities. The ultimate impact to the Company is unknown, but management expects continued interruptions to day-to-day business activities, impacts to claim and premium activity, investment values, as well as possible impacts to liquidity.

B. Troubled Debt Restructuring: Debtors

Not applicable at December 31, 2021 and 2020.

C. Other Disclosures

Assets in the amount of \$55,121,503 and \$56,351,118 at December 31, 2021 and 2020, respectively, were on deposit with government authorities or trustees as required by law.

D. Business Interruption Insurance Recoveries

The Company has reported no recoveries for business interruption for the years ended December 31, 2021 and 2020.

E. State Transferable and Non-Transferable Tax Credits

The Company did not have state transferable or non-transferable tax credits at December 31, 2021 and 2020.

F. Subprime Mortgage-Related Risk Exposure

- (1) The Company's investment strategy of providing safety and preservation of capital, sufficient liquidity to meet cash flow requirements and the attainment of a competitive after-tax investment return is supported by a well diversified portfolio consisting of many different types of investments. The portion of the Company's investment portfolio with subprime mortgage-related risk exposure is relatively small in comparison to the overall investment portfolio, and consists mainly of investment grade securities with no exposure to collateralized debt obligations. All mortgage related investments are monitored closely as part of the quarterly investment review performed by the Anthem Investment Impairment Review Committee.
- (2) The Company did not carry investments in subprime mortgage loans in its portfolio at December 31, 2021 or 2020.
- (3) The Company did not have subprime mortgage-related risk exposure at December 31, 2021 or 2020.
- (4) The Company did not underwrite Mortgage Guaranty or Financial Guaranty insurance coverage at December 31, 2021 or 2020.

G. Retained Assets

The Company does not have retained assets at December 31, 2021 and 2020.

H. Insurance-Linked Securities Contracts

Not applicable.

I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy

Not applicable.

22. Events Subsequent

Subsequent events have been considered through March 30, 2022 for the statutory statement issued on March 31, 2022. There were no events occurring subsequent to December 31, 2021 requiring recognition or disclosure.

23. Reinsurance

A. Ceded Reinsurance Report

Section 1 - General Interrogatories

(1) Are any of the reinsurers that are listed in Schedule S as non-affiliated owned in excess of 10% or controlled, either directly or indirectly, by the Company or by any representative, officer, trustee, or director of the Company?

Yes () No (X)

If yes, give full details.

(2) Have any policies issued by the Company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10% or controlled, directly or indirectly, by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?

Yes () No (X)

If yes, give full details.

Section 2 - Ceded Reinsurance Report - Part A

(1) Does the Company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credits?

Yes () No (X)

If yes, give full details.

(2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes () No (X)

If yes, give full details.

Section 3 - Ceded Reinsurance Report - Part B

(1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the Company may consider the current or anticipated experience of the business reinsured in making this estimate.

\$0

(2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in

force or which had existing reserves established by the Company as of the effective date of the agreement?

Yes () No (X)

If yes, give full details.

B. Uncollectible Reinsurance

The Company has no uncollectible reinsurance at December 31, 2021 and 2020.

C. Commutation of Ceded Reinsurance

The Company has not commuted ceded reinsurance during 2021 and 2020.

D. Certified Reinsurer Rating Downgraded or Status Subject Revocation

The Company has no downgraded certified reinsurer ratings or status subject to revocations during 2021 and 2020.

E. Reinsurance Credit

- (1) Not applicable.
- (2) Not applicable.
- (3) Not applicable.
- (4) Not applicable.
- (5) Not applicable.

24. Retrospectively Rated Contracts & Contracts Subject to Redetermination

- **A.** The Company sells accident and health policies for which the premiums vary based on loss experience. The Company estimates retrospective premium adjustments through the review of each retrospectively rated account, comparing the claim development with that anticipated in the policy contracts.
- **B.** The Company records accrued retrospective premium as an adjustment to earned premium.
- C. The amount of net premiums written by the Company at December 31, 2021 and 2020 that were subject to retrospective rating features was \$758,667,182 and \$949,546,071, respectively, which represented 100.0% and 99.9%, respectively, of the total net premiums written.
- D. Not applicable.

E. Risk-Sharing Provisions of the ACA

(1)	1) Did the reporting entity write accident and health insurance premium that is subject to the Affordable Care Act risk-sharing provisions (YES/NO)?							
(2)		pact of Risk-Sharing Provisions of the Affordable Care Act on Admitted Assets, bilities and Revenue for the Current Year						
	a.	Permanent ACA Risk Adjustment Program						
		Assets						
		 Premium adjustments receivable due to ACA Risk Adjustment (including high risk pool payments) 	\$	221,608				
		Liabilities						
		2. Risk adjustment user fees payable for ACA Risk Adjustment	\$	9				
		3. Premium adjustments payable due to ACA Risk Adjustment (including high risk pool premiums)	\$	_				
		Operations (Revenue & Expense)						
		4. Reported as revenue in premium for accident and health contracts (written/collected) due to ACA Risk Adjustment	\$	257,871				
		5. Reported in expenses as ACA risk adjustment user fees (incurred/paid)	\$	(17)				
	b.	Transitional ACA Reinsurance Program						
		Assets						
		1. Amounts recoverable for claims paid due to ACA Reinsurance	\$					
		Amounts recoverable for claims unpaid due to ACA Reinsurance (contra liability)	\$	_				
		3. Amounts receivable relating to uninsured plans for contributions for ACA Reinsurance	\$					
		Liabilities						
		4. Liabilities for contributions payable due to ACA Reinsurance - not reported as ceded premium	\$					
		5. Ceded reinsurance premiums payable due to ACA Reinsurance	\$					
		 Liability for amounts held under uninsured plans contributions for ACA Reinsurance 	\$					
		Operations (Revenue & Expense)						
		7. Ceded reinsurance premiums due to ACA Reinsurance	\$					
		8. Reinsurance recoveries (income statement) due to ACA Reinsurance payments or expected payments	\$	_				
		9. ACA Reinsurance contributions - not reported as ceded premium	\$	_				
	c.	Temporary ACA Risk Corridors Program						
		Assets						
		1. Accrued retrospective premium due to ACA Risk Corridors Liabilities						
		Reserve for rate credits or policy experience rating refunds due to ACA Risk Corridors	\$	_				
		Operations (Revenue & Expense)						
		3. Effect of ACA Risk Corridors on net premium income (paid/received)	\$					
		4. Effect of ACA Risk Corridors on change in reserves for rate credits	\$	_				
		Line items where the amount is zero is due to no balance and/or no activity as of the reporting date.						

(3) Roll-forward of prior year ACA risk-sharing provisions for the following asset (gross of any nonadmission) and liability balances, along with the reasons for adjustments to prior year balance.

Prior Year on Business Written Before December 31 of the	Business Potoro Door	Wwitton.						the Repor	alances as of rting Date
Prior Year	the Prior	mber 31 of	Prior Year Accrued Less Payments (Col 1-3)	Prior Year Accrued Less Payments (Col 2-4)	To Prior Year Balances	To Prior Year Balances		Cumulative Balance from Prior Years (Col 1-3+7)	Cumulative Balance from Prior Years (Col 2-4+8)
1 2	3	4	5	6	7	8		9	10
Receivable (Payable)	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Ref	Receivable	(Payable)
a. Permanent ACA Risk Adjustment Program									
1. Premium adjustments receivable (including high risk pool payments) \$ 1,357,283 \$ -	\$ 415,219	s –	\$ 942,064	s –	\$ (720,456)	s —	A	\$ 221,608	s –
2. Premium adjustments (payable) (including high risk pool premiums) \$ — \$ 848,309	s –	\$ 549,857	s –	\$ 298,452	s –	\$(298,452)	В	s —	s –
3. Subtotal ACA Permanent Risk Adjustment Program \$ 1,357,283 \$ 848,309	\$ 415,219	\$ 549,857	\$ 942,064	\$ 298,452	\$ (720,456)	\$ (298,452)		\$ 221,608	s –
b. Transitional ACA Reinsurance Program									
Amounts recoverable for claims paid \$ \$ \$	s –	s –	s –	s –	s –	s <u> </u>	С	s –	s _
Amounts recoverable for claims unpaid (contra liability) \$ - \$ -	s –	s –	s –	s –	s –	s –	D	s —	s –
3. Amounts receivable relating to uninsured plans \$ - \$ -	s –	s —	s —	s –	s –	s —	Е	s —	s –
4. Liabilities for contributions payable due to ACA Reinsurance - not reported as ceded premium \$ \$ \$	s —	s —	\$ —	\$ —	s —	s —	F	s —	s —
5. Ceded reinsurance premiums payable \$ \$	s –	s –	s –	s –	s –	s –	G	s –	s –
6. Liability for amounts held under uninsured plans \$ \$	s –	s –	s –	s –	s –	s –		s –	s –
7. Subtotal ACA Transitional Reinsurance Program \$ - \$ -	s –	s –	s –	s –	s –	s –		s –	s –
c. Temporary ACA Risk Corridors Program									
Accrued retrospective premium \$ - \$ -		s –	s –	s –		s –	I	s –	s –
Reserve for rate credits or policy experience rating refunds S — \$ —	s –	s –	s –	s –	s –	s –	J	s –	s –
3. Subtotal ACA Risk Corridors Program \$ \$ \$	s –	s —	s –	s –	s –	s –		s –	s –
d. Total for ACA Risk Sharing Provisions \$ 1,357,283 \$ 848,309	\$ 415,219	\$ 549,857	\$ 942,064	\$ 298,452	\$ (720,456)	\$(298,452)		\$ 221,608	s <u> </u>

Explanations of Adjustments

- A Adjustments were made to reflect the ending balance in the Centers for Medicare & Medicaid Services "Summary Report on Permanent Risk Adjustment Transfers for the 2020 Benefit Year."
- B Adjustments were made to reflect the ending balance in the Centers for Medicare & Medicaid Services "Summary Report on Permanent Risk Adjustment Transfers for the 2020 Benefit Year."
- C Not applicable.
- D Not applicable.
- E Not applicable.
- F Not applicable
- G Not applicable.
- H Not applicable.
- I Not applicable
- J Not applicable.

(4) Roll-Forward of Risk Corridors Asset and Liability Balances by Program Benefit Year.

Ris	k Corridors Program Year	Accrued D Prior Year o Written	on Business	Received or the Currer Business	it Year on	Differ	ences	Adj	ustments	nts Unse		Unsettled Balances as of the Reporting Date	
		December Prior	31 of the	Before Dece	Before December 31 of the Prior Year		Prior Year Accrued Less Payments	To Prior Year Balances	To Prior Year Balances		Cumulative Balance from Prior Years (Col 1 - 3 + 7)	Cumulative Balance from Prior Years (Col 2 - 4 + 8)	
		1	2	3	4	5	6	7	8	R	9	10	
		Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	ef	Receivable	(Payable)	
a.	2014												
1.	Accrued retrospective premium	s <u> </u>	s —	s –	s —	s –	s –	s –	s —	A	s —	<u> </u>	
2.	Reserve for rate credits for policy experience rating refunds	s —	s –	s –	s –	s –	s –	s –	s —	В	s —	<u> </u>	
b.	2015												
1.	Accrued retrospective premium	s –	s —	s –	s —	s –	s –	s –	s –	C	s –	s <u> </u>	
2.	Reserve for rate credits for policy experience rating refunds	s —	s –	s –	s –	s —	s –	s –	s —	D	s —	\$ —	
c.	2016												
1.	Accrued retrospective premium	s <u> </u>	s —		s —	s –	s —		s –	Е	s –	<u> </u>	
2.	Reserve for rate credits for policy experience rating refunds	s —	s –	s –	s –	s —	s –	s —	s –	F	s —	\$	
d.	Total for Risk Corridors	s —	s —	s —	s —	s –	s –	s –	s —		s –	\$	

Explanations of adjustments

- A Not applicable.
- B Not applicable
- C Not applicable
- D Not applicable.
- E Not applicable
- F Not applicable.

24E(4)d (Columns 1 through 10) should equal 24E(3)c3 (Column 1 through 10 respectively)

(5) ACA Risk Corridors Receivable as of Reporting Date.

	Risk Corridors Program Year	to l	1 timated Amount be Filed or Final nount Filed with CMS	2 Non-Accrued Amounts for Impairment or Other Reasons	Α	3 Amounts received from CMS	4 sset Balance (Gross f Non-admissions) (1 - 2 - 3)	5 Non-admitted Amount	Net A	6 dmitted Asset (4 - 5)
a.	2014	\$		\$ 	\$		\$ _	\$ _	\$	
b.	2015	\$		\$ 	\$		\$ _	\$ _	\$	
c.	2016	\$	8,305,585	\$ 41,465	\$	8,264,120	\$ _	\$ _	\$	
d.	Total $(a + b + c)$	\$	8,305,585	\$ 41,465	\$	8,264,120	\$ 	\$ 	\$	

24E(5)d (Columns 4) should equal 24E(3)c1 (Column 9) 24E(5)d (Columns 6) should equal 24E(2)c1

25. Change in Incurred Claims and Claim Adjustment Expenses

- **A.** The estimated cost of claims and claim adjustment expense attributable to insured events of prior years decreased by \$10,748,465 during 2021. This is approximately 7.3% of unpaid claims and claim adjustment expenses of \$146,801,581 as of December 31, 2020. The redundancy reflects the decreases in estimated claims and claims adjustment expenses as a result of claims payment during the year, and as additional information is received regarding claims incurred prior to 2021. Recent claim development trends are also taken into account in evaluating the overall adequacy of unpaid claims and unpaid claim adjustment expense.
- **B.** There were no significant changes in methodologies and assumptions used in calculating the liability for unpaid losses and loss adjustment expenses. The impact from COVID-19 on healthcare utilization and medical claims submission patterns has increased estimation uncertainty on our incurred but not reported liability at December 31, 2021. Slowdowns in claims submission patterns and increases in utilization levels for COVID-19 testing and treatment during the fourth quarter of 2021 are the primary factors that lead to the increased estimation uncertainty.

26. Intercompany Pooling Arrangements

Not applicable at December 31, 2021 and 2020.

27. Structured Settlements

Not applicable at December 31, 2021 and 2020.

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

Quarter	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received Within 90 Days of Billing	Actual Rebates Received Within 91 to 180 Days of Billing	Actual Rebates Received More Than 180 Days After Billing
12/31/2021	\$ 5,792,640	\$ 16,302,384	\$ 10,385,551	\$	
9/30/2021	5,603,115	15,392,214	14,954,931	_	
6/30/2021	6,085,875	11,185,992	10,726,978	459,014	
3/31/2021	5,998,852	15,941,144	15,518,694	422,450	
12/31/2020	6,790,234	17,905,378	17,772,397	132,981	
9/30/2020	4,892,357	15,766,992	15,468,417	298,575	
6/30/2020	6,681,633	14,688,515	14,304,260	384,255	
3/31/2020	10,587,094	10,744,674	10,131,800	612,874	
12/31/2019	17,235,073	13,662,873	608,125	_	13,021,949
9/30/2019	16,781,529	13,463,420	9,151,880	7,808	12,706,834
6/30/2019	16,800,208	13,031,895	277,580	12,672,321	30,251
3/31/2019	16,395,648	12,982,569	237,204	12,777,773	71,851

B. Risk Sharing Receivables

Not applicable at December 31, 2021 and 2020.

29. Participating Policies

Not applicable at December 31, 2021 and 2020.

30. Premium Deficiency Reserves

1. Liability carried for premium deficiency reserves	\$	
2. Date of the most recent evaluation of this liability		December 31, 2021
3. Was anticipated investment income utilized in the calculation?	Yes	No X

The Company recorded premium deficiency reserves of \$17,640,697 at December 31, 2020.

31. Anticipated Salvage and Subrogation

The Company took into account estimated anticipated subrogation and other recoveries in its determination of the liability for unpaid claims and reduced the liability by \$1,526,000 and \$2,794,000 at December 31, 2021 and 2020, respectively.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of which is an insurer?	
	If yes, complete Schedule Y, Parts 1, 1A, 2 and 3.	100 [X] 110 []
1.2	If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent, or with such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statement providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (NAIC) in its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting entity subject to standards and disclosure requirements substantially similar to those required by such Act and regulations?	s[X] No[] N/A[]
1.3	State Regulating?	New York
1.4	Is the reporting entity publicly traded or a member of a publicly traded group?	Yes [X] No []
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group.	0001156039
2.1	Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity?	Yes [] No [X]
2.2	If yes, date of change:	
3.1	State as of what date the latest financial examination of the reporting entity was made or is being made.	12/31/2019
3.2	State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released.	12/31/2019
3.3	State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date).	10/01/2021
3.4	By what department or departments? New York State Department of Financial Services	
3.5	Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement filed with Departments?	s [] No [] N/A [X]
3.6	Have all of the recommendations within the latest financial examination report been complied with?	s [X] No [] N/A []
4.1	During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity), receive credit or commissions for or con a substantial part (more than 20 percent of any major line of business measured on direct premiums) of: 4.11 sales of new business?	Yes [] No [X]
4.2	4.12 renewals?	
	4.21 sales of new business? 4.22 renewals?	
5.1	Has the reporting entity been a party to a merger or consolidation during the period covered by this statement?	
0.1	If yes, complete and file the merger history data file with the NAIC.	103 [] NO [X]
5.2	If yes, provide the name of the entity, NAIC Company Code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.	
	1 Name of Entity NAIC Company Code State of Domicile	
6.1	Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended revoked by any governmental entity during the reporting period?	
6.2	If yes, give full information:	
7.1	Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity?	
7.2	If yes, 7.21 State the percentage of foreign control;	٩٧
	7.22 State the nationality(s) of the foreign person(s) or entity(s) or if the entity is a mutual or reciprocal, the nationality of its manager or attorney-in-fact; and identify the type of entity(s) (e.g., individual, corporation or government, manager or attorney in fact).	<u> </u>
	1 2 Time of Entity	

GENERAL INTERROGATORIES

8.1 8.2	Is the company a subsidiary of a depository institution holding compan If the response to 8.1 is yes, please identify the name of the DIHC.	ny (DIHC) or a DIHC itself, regulated by the Federal	Reserv	e Board?		Yes []	No [Х]
8.3 8.4	Is the company affiliated with one or more banks, thrifts or securities fill fresponse to 8.3 is yes, please provide below the names and location regulatory services agency [i.e. the Federal Reserve Board (FRB), the Insurance Corporation (FDIC) and the Securities Exchange Commission	n (city and state of the main office) of any affiliates recommended of the Comptroller of the Currency (OCC), the	egulated	d by a fed	deral	Yes []	No [X]
	1	2	3	4	5	6	1		
	Affiliate Name	Location (City, State)	FRB	OCC	FDIC	SEC			
8.5 8.6	Is the reporting entity a depository institution holding company with sig Federal Reserve System or a subsidiary of the reporting entity?					Yes []	No [Х]
0.0	Federal Reserve Board's capital rule?			١١	es [] No [Х]	N/A	[]
9.	What is the name and address of the independent certified public according	ountant or accounting firm retained to conduct the a	ınnual a	udit?					
	Ernst & Young LLP, 111 Monument Circle, Suite 4000, Indianapolis, IN								
10.1	Has the insurer been granted any exemptions to the prohibited non-au requirements as allowed in Section 7H of the Annual Financial Reportilaw or regulation?	ing Model Regulation (Model Audit Rule), or substa	ntially s	imilar sta	te	Yes [1	No [Χl
10.2	If the response to 10.1 is yes, provide information related to this exempton the response to 10.1 is yes, provide information related to this exempton.	ption:						·	•
10.3	Has the insurer been granted any exemptions related to the other requallowed for in Section 18A of the Model Regulation, or substantially sin	milar state law or regulation?	Regulat	ion as		Yes []	No [Х]
10.4	If the response to 10.3 is yes, provide information related to this exemple.	ption:							
10.5	Has the reporting entity established an Audit Committee in compliance					1 No [1	N/A	(1
10.6	If the response to 10.5 is no or n/a, please explain					, (,		
11.	What is the name, address and affiliation (officer/employee of the reposition) of the individual providing the statement of actuarial opinion/certif Reuven Lowenthal, FSA, MAA, Director & Actuary III (employee): 1408	fication?			J				
12.1	Does the reporting entity own any securities of a real estate holding co	ompany or otherwise hold real estate indirectly?				Yes [1	No [X]
		estate holding company					•		•
		rcels involved							
	12.13 Total book/adj	justed carrying value				\$			
12.2	If, yes provide explanation:								
13.	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITI								
13.1	What changes have been made during the year in the United States m	nanager or the United States trustees of the reporti	ng entity	?					
13.2	Does this statement contain all business transacted for the reporting e					Yes []	No []
13.3	Have there been any changes made to any of the trust indentures duri	ing the year?				Yes []	No []
13.4	If answer to (13.3) is yes, has the domiciliary or entry state approved the	he changes?		٠١	es [] No []	N/A	[]
14.1	Are the senior officers (principal executive officer, principal financial of					v			
	similar functions) of the reporting entity subject to a code of ethics, whi a. Honest and ethical conduct, including the ethical handling of actual relationships;					Yes [X	.]	No [J
	b. Full, fair, accurate, timely and understandable disclosure in the period		ity;						
	c. Compliance with applicable governmental laws, rules and regulationd. The prompt internal reporting of violations to an appropriate person								
	e. Accountability for adherence to the code.	or persons identified in the code, and							
14.11	If the response to 14.1 is No, please explain:								
14.2	Has the code of ethics for senior managers been amended?					Yes [1	No 1	χ 1
	If the response to 14.2 is yes, provide information related to amendme	ent(s).				100 [,	.10 [v 1
14.3	Have any provisions of the code of ethics been waived for any of the s					Yes []	No [X 1
	If the response to 14.3 is yes, provide the nature of any waiver(s).						•		•

GENERAL INTERROGATORIES

	Name of Third-Party	a Related Party (Yes/No)	
		Is the Third-Party Agent	
If the response t	to 24.1 is yes, identify the third-party that pays the age	ints and whether they are a related party.	
90 days?		, ,	Yes [] No
			a
Does the reporti	ng entity report any amounts due from parent, subsidi	aries or affiliates on Page 2 of this statement?	Yes [] No
D 45 · · · · · · · · ·			
If answer is yes:		22.21 Amount paid as losses or risk adjustment s	\$
guaranty associa	ation assessments?		Yes [X] No
Does this statem	nent include payments for assessments as described	in the Annual Statement Instructions other than quaranty fund or	
ıı yes, state tile t	amount thereof at December 31 of the current year:		
obligation being	reported in the statement?		Yes [] No
Were any assets	s reported in this statement subject to a contractual ob	oligation to transfer to another party without the liability for such	
		20.23 Trustees, supreme or grand (Fraternal Only)	\$
		20 00 T	
policy loans):		20.21 To directors or other officers	\$
	loans outstanding at the end of year (inclusive of Sep	arate Accounts, exclusive of	
		(Fraternal Only)	\$
. Ottai airiourit 106	and daming the year (morasive of departite Accounts,		
Accounting Prince	ciples)?	ovelucino of policy loans): 00 44 To disasters as alternative	Yes [] No
Has this stateme	ent been prepared using a basis of accounting other the	FINANCIAL han Statutory Accounting Principles (e.g., Generally Accepted	
part of any of its	officers, directors, trustees or responsible employees	that is in conflict with the official duties of such person?	Yes [X] No
Has the reporting	g entity an established procedure for disclosure to its	board of directors or trustees of any material interest or affiliation on the	Yes [X] No
Does the reporti	ng entity keep a complete permanent record of the pro-	oceedings of its board of directors and all subordinate committees	Yes [X] No
	or sale of all investments of the reporting entity passe	d upon either by the board of directors or a subordinate committee	V [V] N-
	BOAL	RD OF DIRECTORS	
Number			Amount
Bankers Association (ABA) Routing			
American			
	Bankers Association (ABA) Routing Number Is the purchase thereof? Does the reportithereof? Has the reporting part of any of its Has this statemed Accounting Print Total amount lost Total amount of policy loans): Were any assetion being if yes, state the guaranty associal fanswer is yes: Does the reportil fyes, indicate a Does the insure 90 days?	Bankers Association (ABA) Routing Number Issuing or Confirming Bank Name BOAI Is the purchase or sale of all investments of the reporting entity passe thereof? Does the reporting entity keep a complete permanent record of the prothereof? Has the reporting entity an established procedure for disclosure to its part of any of its officers, directors, trustees or responsible employees Has this statement been prepared using a basis of accounting other the Accounting Principles)? Total amount loaned during the year (inclusive of Separate Accounts, Total amount of loans outstanding at the end of year (inclusive of Separate Accounts) Were any assets reported in this statement subject to a contractual of obligation being reported in the statement? If yes, state the amount thereof at December 31 of the current year: Does this statement include payments for assessments as described guaranty association assessments? If answer is yes: Does the reporting entity report any amounts due from parent, subsidit fyes, indicate any amounts receivable from parent included in the PaDoes the insurer utilize third parties to pay agent commissions in whice 90 days? If the response to 24.1 is yes, identify the third-party that pays the agent include in the pay	Bankers Association (ABA) Routing Number BOARD OF DIRECTORS Is the purchase or sale of all investments of the reporting entity passed upon either by the board of directors or a subordinate committee thereof? Does the reporting entity keep a complete permanent record of the proceedings of its board of directors and all subordinate committees thereof? As the reporting entity an established procedure for disclosure to its board of directors or trustees of any material interest or affiliation on the part of any of its officers, directors, trustees or responsible employees that is in conflict with the official duties of such person? FINANCIAL Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Generally Accepted Accounting Principles)? Total amount loaned during the year (inclusive of Separate Accounts, exclusive of policy loans): 20.11 To directors or other officers. 20.12 To stockholders not officers. 20.12 Trustees, supreme or grand (Fratemal Only) Were any assets reported in this statement subject to a contractual obligation to transfer to another party without the liability for such obligation being reported in the statement? If yes, state the amount thereof at December 31 of the current year: 21.21 Rented from others. 21.22 Alother 21.22 Alother 22.21 Amount paid as expenses. 22.22 To mount paid as sepanses. 22.22 Amount paid as sepanses. 22.22 Amount paid as sepanses. 22.22 Amount paid as expenses. 22.23 Other amounts paid. Does the reporting entity report any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement? If yes, inclicate any amounts receivable from parent included in the Page 2 amount. Does the reporting entity report any amounts due from parent included in the Page 2 amount. Does the number utilize brito parties to pay agent commissions in which the amounts advanced by the third parties are not settled in full within 90 days? If the response to 24.1 is yes, identify the third-party that p

GENERAL INTERROGATORIES

25.02	? If no, give full and complete information relating thereto						
25.03	For securities lending programs, provide a description of the program including whether collateral is carried on or off-balance sheet. (an alternative is to refer See Notes 5E and 17.	rence Note 17 where this information is also provided)					
25.04	For the reporting entity's securities lending program, report amount of collater Instructions.	eral for conforming programs as outlined in the Risk-Based Capit	tal \$			15 , 18(0,624
25.05	For the reporting entity's securities lending program, report amount of collater	eral for other programs.	\$				
25.06	Does your securities lending program require 102% (domestic securities) and outset of the contract?	d 105% (foreign securities) from the counterparty at the	[X]	No [. 1	N/A	[]
25.07	Does the reporting entity non-admit when the collateral received from the cou	unterparty falls below 100%?	[X]	No []	N/A	[]
25.08	B Does the reporting entity or the reporting entity 's securities lending agent util conduct securities lending?	lize the Master Securities lending Agreement (MSLA) to Yes	[X]	No [1	N/A	[]
25.09	9 For the reporting entity's securities lending program state the amount of the fo	following as of December 31 of the current year:					
	25.092 Total book adjusted/carrying value of reinvested colla	ed on Schedule DL, Parts 1 and 2ateral assets reported on Schedule DL, Parts 1 and 2iability page.	\$. 15, 180	0,624
26.1	Were any of the stocks, bonds or other assets of the reporting entity owned a control of the reporting entity, or has the reporting entity sold or transferred a force? (Exclude securities subject to Interrogatory 21.1 and 25.03)	any assets subject to a put option contract that is currently in		Yes [Х]	No []
26.2	If yes, state the amount thereof at December 31 of the current year:	26.21 Subject to repurchase agreements 26.22 Subject to reverse repurchase agreements 26.23 Subject to dollar repurchase agreements 26.24 Subject to reverse dollar repurchase agreements 26.25 Placed under option agreements 26.26 Letter stock or securities restricted as to sale - excluding FHLB Capital Stock 26.27 FHLB Capital Stock 26.28 On deposit with states 26.29 On deposit with other regulatory bodies 26.30 Pledged as collateral - excluding collateral pledge an FHLB 26.31 Pledged as collateral to FHLB - including assets backing funding agreements 26.32 Other	\$\$\$\$\$\$\$\$ ed to\$.55,12	21,503
26.3	For category (26.26) provide the following:						
							_
	1 Nature of Restriction	2 Description		Am	3 nount		
		Description		Am	nount		
27.1		Description		Am	nount		
27.1 27.2	Does the reporting entity have any hedging transactions reported on Schedul	Description		Am Yes [nount	No [)	 X]
27.2	Does the reporting entity have any hedging transactions reported on Schedul If yes, has a comprehensive description of the hedging program been made a	Description		Am Yes [nount	No [)	Х]
27.2	Does the reporting entity have any hedging transactions reported on Schedul If yes, has a comprehensive description of the hedging program been made all fino, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY:	Description le DB?available to the domiciliary state?		Am Yes []	No [)] X] []
27.2 INES 2	Does the reporting entity have any hedging transactions reported on Schedul If yes, has a comprehensive description of the hedging program been made a If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarant If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special a	Description lle DB?		Yes [Yes [Yes []	No [)] X] []
27.2 INES 2 27.3	Does the reporting entity have any hedging transactions reported on Schedul If yes, has a comprehensive description of the hedging program been made at If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarant If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special at 27.42 Permitted.	Description le DB?		Yes [Yes [Yes [Yes [Yes []]]	No [) N/A No [) No [)] X] []
27.2 INES 2 27.3	Does the reporting entity have any hedging transactions reported on Schedul If yes, has a comprehensive description of the hedging program been made at If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarants. If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special at 27.42 Permitted 27.43 Other acc. By responding YES to 27.41 regarding utilizing the special accounting provisity following:	Description le DB? available to the domiciliary state? tees subject to fluctuations as a result of interest rate sensitivity? accounting provision of SSAP No. 108 d accounting practice counting guidance sions of SSAP No. 108, the reporting entity attests to the	 : [] ?	Yes [Yes [Yes [Yes [Yes []]]]	No [) N/A No [) No [) No [No	X] [] X]
27.2 INES 2 27.3 27.4	Does the reporting entity have any hedging transactions reported on Schedul If yes, has a comprehensive description of the hedging program been made at If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarants. If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special at 27.42 Permitted 27.43 Other acc.	Description available to the domiciliary state?	· · · · · · · · · · · · · · · · · · ·	Yes []]]]	No [) N/A No [) No [) No [No	X] [] X]
27.2 INES 2 27.3 27.4	Does the reporting entity have any hedging transactions reported on Schedul If yes, has a comprehensive description of the hedging program been made at If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarants. If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special a 27.42 Permitted 27.43 Other acc. By responding YES to 27.41 regarding utilizing the special accounting provision following: The reporting entity has obtained explicit approval from the domicilia Hedging strategy subject to the special accounting provisions is con: Actuarial certification has been obtained which indicates that the hed reserves and provides the impact of the hedging strategy within the Actuarial Officer Certification has been obtained which indicates that Hedging Strategy within VM-21 and that the Clearly Defined Hedging its actual day-to-day risk mitigation efforts.	Description Ile DB?		Yes [No [) No [) No [)	X] X] X]
27.2 INES 2 27.3 27.4	Does the reporting entity have any hedging transactions reported on Schedul If yes, has a comprehensive description of the hedging program been made at If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarants. If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special a 27.42 Permitted 27.43 Other acc. By responding YES to 27.41 regarding utilizing the special accounting provisifollowing: The reporting entity has obtained explicit approval from the domicilia. Hedging strategy subject to the special accounting provisions is con: Actuarial certification has been obtained which indicates that the hed reserves and provides the impact of the hedging strategy within the Financial Officer Certification has been obtained which indicates that Hedging Strategy within VM-21 and that the Clearly Defined Hedging its actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 31 of the current issuer, convertible into equity?	Description available to the domiciliary state? available to the domiciliary state? accounting provision of SSAP No. 108 d accounting practice counting guidance sions of SSAP No. 108, the reporting entity attests to the ary state. Insistent with the requirements of VM-21. dging strategy is incorporated within the establishment of VM-21 Actuarial Guideline Conditional Tail Expectation Amount. at the hedging strategy meets the definition of a Clearly Defined ag Strategy is the hedging strategy being used by the company in at year mandatorily convertible into equity, or, at the option of the		Am Yes [] No [Yes [Ye		No [3] N/A No [3] No [7] No [7] No [7]	X] [] X]
27.2 INES 2 27.3 27.4 27.5	Does the reporting entity have any hedging transactions reported on Schedul If yes, has a comprehensive description of the hedging program been made at If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarants. If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special at 27.42 Permitted 27.43 Other according YES to 27.41 regarding utilizing the special accounting provision following: • The reporting entity has obtained explicit approval from the domiciliation. Hedging strategy subject to the special accounting provisions is contact to the special accounting provisions is contact to the hedging strategy within the Account of the h	Description Ile DB?	;; []	Am Yes [] No [Yes [Ye]]]]	No [) No [) No [) No [)	X] [] X] X]
27.2 INES 2 27.3 27.4 27.5 28.1 28.2 29.	Does the reporting entity have any hedging transactions reported on Schedul If yes, has a comprehensive description of the hedging program been made at If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarant If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special a 27.42 Permitted 27.43 Other acc By responding YES to 27.41 regarding utilizing the special accounting provisi following: The reporting entity has obtained explicit approval from the domicilia Hedging strategy subject to the special accounting provisions is cone. Actuarial certification has been obtained which indicates that the hed reserves and provides the impact of the hedging strategy within the Financial Officer Certification has been obtained which indicates that Hedging Strategy within VM-21 and that the Clearly Defined Hedging its actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 31 of the current issuer, convertible into equity? If yes, state the amount thereof at December 31 of the current year. Excluding items in Schedule E - Part 3 - Special Deposits, real estate, mortgoffices, vaults or safety deposit boxes, were all stocks, bonds and other secucustodial agreement with a qualified bank or trust company in accordance with a part of the secucus of the secucis of the secucis of the secucis of the secucis of the	Description Ile DB? available to the domiciliary state? Yes tees subject to fluctuations as a result of interest rate sensitivity? accounting provision of SSAP No. 108 d accounting practice counting guidance sions of SSAP No. 108, the reporting entity attests to the arry state. Insistent with the requirements of VM-21. dging strategy is incorporated within the establishment of VM-21 Actuarial Guideline Conditional Tail Expectation Amount. at the hedging strategy meets the definition of a Clearly Defined ag Strategy is the hedging strategy being used by the company in at year mandatorily convertible into equity, or, at the option of the gage loans and investments held physically in the reporting entity unities, owned throughout the current year held pursuant to a ith Section 1, III - General Examination Considerations, F. the NAIC Financial Condition Examiners Handbook?	;; []	Am Yes [] No [Yes [Ye]]]]	No [) No [) No [) No [)	X] X] X] X]
27.2 INES 2 27.3 27.4 27.5 28.1 28.2 29.	Does the reporting entity have any hedging transactions reported on Schedul If yes, has a comprehensive description of the hedging program been made at If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarant If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special a 27.42 Permitted 27.43 Other acc. By responding YES to 27.41 regarding utilizing the special accounting provisifollowing: The reporting entity has obtained explicit approval from the domicilia Hedging strategy subject to the special accounting provisions is come. Actuarial certification has been obtained which indicates that the her reserves and provides the impact of the hedging strategy within the engarress and provides the impact of the hedging strategy within the engarress and provides the impact of the hedging strategy within the engarress and provides the impact of the hedging strategy within the engarress and provides the impact of the hedging strategy within the engarress and provides the impact of the hedging strategy within the engarress and provides the impact of the hedging strategy within the engarress and provides the impact of the hedging strategy within the engarress and provides the impact of the hedging strategy within the engarress and provides the impact of the hedging strategy within the engarress and provides the impact of the hedging strategy within the engarress and provides the impact of the hedging strategy within the engarress and provides the impact of the hedging strategy within the engarress and provides the impact of the hedging strategy within the engarress and provides the impact of the hedging strategy within the engarress and provides the impact of the hedging strategy within the engarress and provides the impact of the hedging strategy within the engarress and provides the impact of the hedging strategy within the engarress and provides the impact of t	Description Ile DB? available to the domiciliary state? Available to the domiciliary state? Available to the domiciliary state? Accounting provision of SSAP No. 108 Accounting practice Counting guidance Bions of SSAP No. 108, the reporting entity attests to the Actuarial guidance Bions of SSAP No. 108, the reporting entity attests to the Actuarial Guideline Conditional Tail Expectation Amount. Actuarial Guideline Conditional Tail Expectation Amount. At the hedging strategy meets the definition of a Clearly Defined and Strategy is the hedging strategy being used by the company in At year mandatorily convertible into equity, or, at the option of the place of the current year held pursuant to a sith Section 1, III - General Examination Considerations, F. the NAIC Financial Condition Examiners Handbook? Accounting provision of SSAP No. 108 Acco		Am Yes [Yes]]] X]	No [) N/A No [) No [) No [] No []	X] X] X] X]

GENERAL INTERROGATORIES

29.02	For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location	
	and a complete explanation:	

1	2	3
Name(s)	Location(s)	Complete Explanation(s)

29.03 l	Have there been any changes, including name changes, in the custodian(s) identified in 29.01 during the current year?	Yes [] No	o [X]
---------	---	-------	------	-------	---

29.04 If yes, give full and complete information relating thereto:

1	2	3	4
Old Custodian	New Custodian	Date of Change	Reason

29.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1 Name of Firm or Individual	2 Affiliation
Anthem, Inc.	I
Loomis, Sayles & Company, LP	U
-,	

29.06 For those firms or individuals listed in the table for 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1	2	3	4	5
				Investment
				Management
Central Registration Depository Number				Agreement
Depository Number	Name of Firm or Individual	Legal Entity Identifier (LEI)	Registered With	(IMA) Filed
			Securities Exchange	
105377	Loomis, Sayles & Company, LP	JIZPN2RX3UMNOYIDI313	Commission	NO
	,, , . ,		Securities Exchange	
107717	MacKay Shields LLC		Commission	NO
101711	madriay difference EEG	0.100001722001 071101710		

30.1	Does the reporting entity have any diversified mutual funds reported in Schedule D, Part 2 (diversified according to the Securities and						
	Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5(b)(1)])?	Yes []	No	[)	Χ]	

30.2 If yes, complete the following schedule:

1	2	3
		Book/Adjusted
CUSIP#	Name of Mutual Fund	Carrying Value
30.2999 - Total		0

30.3 For each mutual fund listed in the table above, complete the following schedule:

1	2	3	4
		Amount of Mutual	
		Fund's Book/Adjusted	
		Carrying Value	
	Name of Significant Holding of the	Attributable to the	Date of
Name of Mutual Fund (from above table)	Mutual Fund	Holding	Valuation

GENERAL INTERROGATORIES

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
			Excess of Statement
			over Fair Value (-), or
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
31.1 Bonds	320,250,647	331,023,457	10,772,810
31.2 Preferred stocks	0		0
31.3 Totals	320,250,647	331,023,457	10,772,810

31.4	Describe the sources of methods utilized in determining the fair values.				
	Fair values were obtained from third-party pricing sources. If a security was not priced by a third-party pricing source, internal analytical systems or broker quotes were utilized.				
32.1	Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?	Yes []	No [[X]
32.2	If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?	Yes []	No []
32.3	If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D: N/A				
33.1 33.2	Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed?	Yes []	Х]	No []
34.	By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security: a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available. b. Issuer or obligor is current on all contracted interest and principal payments. c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal. Has the reporting entity self-designated 5GI securities?	Yes [1	No [[X]
35.	By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security: a. The security was purchased prior to January 1, 2018. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators. d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO. Has the reporting entity self-designated PLGI securities?	Yes []	No [[X]
36.	By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund: a. The shares were purchased prior to January 1, 2019. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019. d. The fund only or predominantly holds bonds in its portfolio. e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO. f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed. Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?	Yes [1	No [[X]
37.	By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following: a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date. b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties. c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review. d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a - 37.c are reported as long-term investments. Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria? Yes [l No [. х	N/A	1 A

GENERAL INTERROGATORIES

OTHER

1	2
Name	Amount Paid
Blue Cross Blue Shield Association	43,408
	,

39.1 Amount of payments for legal expenses, if any? \$\,_1,075,476\$

39.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal expenses during the period covered by this statement.

1	2
Name	Amount Paid
Nelson Mullins Rileys	304,965
Omelveny & Myers	555,564

40.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures in connection with matters before legislative bodies, officers or departments of government during the period covered by this statement.

1	2
Name	Amount Paid
Hinman Straub	29,034
Pitta Bishop Del Giorno & Giblin LLC	24.433
	,

Lobbying expenses disclosed reflect amounts reported in the Lobbyist Disclosure Reports filed with the Secretary of State. The amount may include expenses that may have been paid by an affiliate on behalf of the Company and, as a result, may not be included in the Underwriting Gain reported on page 4 of the 2021 Annual Statement."

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1 1.2	Does the reporting entity have any direct Medicare Supplement Insurance in force? If yes, indicate premium earned on U.S. business only.		
1.3	What portion of Item (1.2) is not reported on the Medicare Supplement Insurance E		
	1.31 Reason for excluding	•	
.4	Indicate amount of earned premium attributable to Canadian and/or Other Alien no	t included in Item (1.2) above	¢
. 4 .5	Indicate total incurred claims on all Medicare Supplement Insurance.		
.6	Individual policies:	Most current three years:	Ψ
		1.61 Total premium earned	\$
		1.62 Total incurred claims	\$0
		1.63 Number of covered lives	
		All years prior to most current three years:	
		1.64 Total premium earned 1.65 Total incurred claims	
		1.66 Number of covered lives	•
.7	Group policies:	Most current three years:	
		1.71 Total premium earned	\$0
		1.72 Total incurred claims	
		1.73 Number of covered lives	
		All years prior to most current three years: 1.74 Total premium earned	
		1.74 Total premium earned	\$
		1.76 Number of covered lives	
2.	Health Test:		
		1 2 Current Year Prior Year	
	2.1 Premium Numerator		
	2.2 Premium Denominator		
	2.3 Premium Ratio (2.1/2.2)	1.0001.000	
	2.4 Reserve Numerator		
	2.5 Reserve Denominator		
	2.6 Reserve Ratio (2.4/2.5)	1.0001.000	
3.2	If yes, give particulars:		
l.1	Have copies of all agreements stating the period and nature of hospitals', physiciar dependents been filed with the appropriate regulatory agency?		Yes [X] No []
1.2	If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these	agreements include additional benefits offered?	Yes [] No []
5.1	Does the reporting entity have stop-loss reinsurance?		Yes [] No [X]
5.2	If no, explain:		
	The Company retains all risk.		
5.3	Maximum retained risk (see instructions)	5.31 Comprehensive Medical	\$
		5.32 Medical Only	\$
		5.33 Medicare Supplement	
		5.34 Dental & Vision	·
		5.35 Other Limited Benefit Plan5.36 Other	
6.	Describe arrangement which the reporting entity may have to protect subscribers a hold harmless provisions, conversion privileges with other carriers, agreements wit agreements:	and their dependents against the risk of insolvency including the providers to continue rendering services, and any other	
	If the Company becomes insolvent, Anthem, Inc. has agreed to assume all contract contracts contain appropriate hold harmless provisions.		
'.1	Does the reporting entity set up its claim liability for provider services on a service of	date basis?	Yes [X] No []
.2	If no, give details		
8.	Provide the following information regarding participating providers:	8.1 Number of providers at start of reporting year	
		8.2 Number of providers at end of reporting year	114,35
.1	Does the reporting entity have business subject to premium rate guarantees?		Yes [] No [X]
).2	If yes, direct premium earned:	9.21 Business with rate guarantees between 15-36 months9.22 Business with rate guarantees over 36 months	

GENERAL INTERROGATORIES

10.1	Does the reporting entity have Incentive P	ool, Withhold or Bonus Arrangements in its provider contracts?	Yes [X]	No []
10.2	If yes:	10.21 Maximum amount payable bonuses			
		10.22 Amount actually paid for year bonuses	\$	11,4	25,994
		10.23 Maximum amount payable withholds			
		10.24 Amount actually paid for year withholds	\$		
11.1	Is the reporting entity organized as:				
		11.12 A Medical Group/Staff Model,	Yes []	No [[X]
		11.13 An Individual Practice Association (IPA), or, .	Yes []	No [[X]
		11.14 A Mixed Model (combination of above)?	Yes []	No [X]
11.2	Is the reporting entity subject to Statutory	Minimum Capital and Surplus Requirements?	Yes [X]	No []
11.3	If yes, show the name of the state requiring	g such minimum capital and surplus.			w York
11.4	If yes, show the amount required	-	\$	94,8	33,398
11.5	Is this amount included as part of a contin	gency reserve in stockholder's equity?	Yes [X]	No []
11.6	If the amount is calculated, show the calculated	ulation			
	Please see attached Report 16A from the	Company's Supplement.			
12.	List service areas in which reporting entity	is licensed to operate:			
		1			
		Name of Service Area			
		Alhany			

1
Name of Service Area
Albany
Bronx
Clinton
Columbia
Delaware
Duchess
Essex
Fulton
Greene
Kings
Montgomery
Nassau
New York
Orange
Putnam
Queens
Rensselaer
Richmond
Rockland
Saratoga
Schenectady
Schoharie
Suffolk
Sullivan
Ulster
Warren
Washington
Westchester

13.1	.1 Do you act as a custodian for health savings accounts?					Yes [] No	[X]	
13.2	3.2 If yes, please provide the amount of custodial funds held as of the reporting date.					\$		
13.3	Do you act as an administrator for health savings ac	counts?					Yes [] No	[X]
13.4	If yes, please provide the balance of funds administe	ered as of the rep	porting date				\$	
14.1 14.2	Are any of the captive affiliates reported on Schedul If the answer to 14.1 is yes, please provide the follow		orized reinsurers?			Yes [] No [] N	/A [X]
	1	2	3	4	Assets	Supporting Reserve	e Credit	1
		NAIC			5	6	7	
		Company	Domiciliary	Reserve	Letters of	Trust		
	Company Name	Code	Jurisdiction	Credit	Credit	Agreements	Other	

Other

Agreements

Credit

Company Name

15.	Provide the following for individual ordinary life insurance* policies (U.S. business only) for the current year (prior to reinsurance assumed or ceded):					
		15.1 Direct Premium Written	\$			
		15.2 Total Incurred Claims	\$			
		15.3 Number of Covered Lives				
		*Ordinary Life Insurance Includes				
		Term(whether full underwriting, limited underwriting, jet issue, "short form app")				
		Whole Life (whether full underwriting, limited underwriting, jet issue, "short form app")				
		Variable Life (with or without secondary gurarantee)				
		Universal Life (with or without secondary gurarantee)				
		Variable Universal Life (with or without secondary gurarantee)				
16.	Is the reporting entity licensed	d or chartered, registered, qualified, eligible or writing business in at least two states?	Yes [X] No []	
16.1		y assume reinsurance business that covers risks residing in at least one state other than the state of y?	Yes [] No []	

REPORT #16A

Calculations Of The Escrow Deposit And Contingent Reserve Health Department Regulation Part 98-1.11(e) and (f)

I. Escrow Deposit

1.	Projected 2021 Hospital and Medical Expenses	
	(12/31/20 NY Supplement, page NY6, In. 16, col. 9)	844,891,325
2.	Escrow Deposit Requirement (5% of projected 2021 hospital and medical expenses) (a)	42,244,566

II. Contingent Reserve*

1.	Direct Business (NAIC Health Blank, page 8, Underwriting & Investment Part 1 - Premiums, In. 12, col. 1)	758,667,182
2.	Approved Reinsurance Ceded (Report #16B, col. 2) (b)	
3.	Net Premium Income (Net of approved reinsurance) for: *	
	3.i) All lines of business EXCEPT:	
	Essential Plan, FIDA, Medicaid Managed Care, Medicaid Advantage, HARP, MLTC Program (MLTC-Partial, Medicaid Advantage Plus ("MAP"), PACE) and HIV SNP	
	(pages NY7-NY9, In. 2.5, all columns EXCEPT: cols. 33, 35, 37, 41, 43, 45)	758,667,182
	3.ii) Essential Plan, HARP, Medicaid Managed Care, Medicaid Advantage and HIV SNP programs (pages NY8-NY9, In. 2.5, cols. 33, 35, 41, 43)	.0
	LESS: Value Based Payment ("VBP") Supplemental Programs	0
	3.iii) MLTC Program (MLTC-Partial, MAP, PACE) (page NY9, In. 2.5, col. 37)	
	3.iv) FIDA-IDD (page NY9, In. 2.5, col. 45)	0
4.	Contingent Reserve, not including the 2% Point of Service Contingent Reserve Requirement.(c)	94,833,398
5.	2% Point of Service Contingent Reserve Requirement.(d)	
6.	Total Contingent Reserve (Ins. 4+5 should equal page NY3, In. 30.11, col. 3).	94,833,398
7.	Escrow Deposit, after offset of the Contingent Reserve (I.In. 2 less II.In. 4; minimum of \$0, should equal page NY3, In. 30.12, col. 3)	0
8.	Total minimum Net Worth (In. 6+7; should equal page NY3, In. 30.13, col. 3)	94,833,398
*Th	e Net Premium Income amount used to calculate the contingent reserve for line 3 are the amounts reported on the Statement of Reven	ue and Evnenses by Line

The Net Premium Income amount used to calculate the contingent reserve for line 3 are the amounts reported on the Statement of Revenue and Expenses by Line of Business Parts 1, 2 & 3 on pages 9 to 12 in the NY Supplement for HMO.

- (b) This entry will equal Net Premium Income, Page NY4, Line 2.5 only if all reinsurance contracts have been approved by the Department of Financial Services. Reinsurance agreements not approved by the Department of Financial Services should not be included in this line.
- (c) For HMO's certified prior to June 29, 2005, Line 5 equals 121/2% of Line 3(ii) PLUS 71/4% of Line 3(iii) PLUS 5% of Line 3(iii) PLUS 6.25% of Line 3(iv).
- (d) The calculation of the Contingent Reserve must show that the HMO meets the 2% Point of Service Contingent Reserve requirement in addition to the standard contingent reserve requirement of 10 NYCRR 98-1.11(e) if the HMO writes out-of-network coverage for POS contracts aside from individual "standardized" POS contracts.

For HMO's certified after June 29, 2005:

If as of 12/31/2021, the HMO has not been certified for a full calendar year, then Line 4 equals 5% of projected premium revenue for the first full year of calendar year operations, i.e., 5% of Page NY6, Line 2.5, column 9 to which the HMO is to add back reinsurance premiums ceded pursuant to a reinsurance contract that has not been approved by the Department of Financial Services.

If as of 12/31/2021, the HMO has been certified for at least one full calendar year, then Line 4 is determined in accordance with the following schedule:

The provisions below pertain to the contingent reserve for the Essential Plan, Medicaid Managed Care, Medicaid Advantage, HARP, HIV SNP, and MLTC Partial Cap (MAP, PACE, FIDA, FIDA-IDD).

Completed Calendar Years of Operations	Line 4 should include This Percent of the amount of Premium in Line 3(i).	P	For Calendar Year Ending	Line 4 should include the Percent of the amount of Premium in Line 3(ii).	PLUS	Line 4 should include the Percent of the amount of Premium in Line 3(iii)	PLUS	Line 4 should include the Percent of the amount of Premium in Line 3(iv).
1 year	5%		2021	7.25%		5.00%		6.25%
2 years	6.50%		2022	7.25%		5.00%		6.25%
3 years	7.50%		2023	8.25%		5.00%		6.25%
4 years	8.50%		2024	9.25%		5.00%		6.25%
5 years	9.50%		2025	10.25%		5.00%		6.25%
6 years	10.50%		2026	11.25%		5.00%		6.25%
7 years	11.50%		2027	12.5%		5.00%		6.25%
8 or more years	12.50%		After 2028	12.5%		5.00%		6.25%

⁽a) Department of Health Regulation 10 NYCRR 98-1.11(f), amended effective 6/29/05, requires the HMO to establish an escrow account in the form of a trust account with a custodian, for which a deed of trust has been approved by the superintendent. Also, based on the added pharmacy benefits to the Medicaid, and HIV SNP benefits packages on October 1, 2011, MCO's must include 100% of the projected pharmacy expenses in the calculation of the 5% escrow requirement that must be on deposit, as of March 31, 2021. Details of the account should be reported in the NAIC Health Blank, Schedule E – Part 3, Special Deposits.

FIVE-YEAR HISTORICAL DATA

		1 2021	2 2020	3 2019	4 2018	5 2017
	Balance Sheet (Pages 2 and 3)					
1.	Total admitted assets (Page 2, Line 28)	431,037,302	425,392,401	408,659,367	434,637,489	525,218,643
2.	Total liabilities (Page 3, Line 24)		245, 190, 660		247,626,320	321,619,879
3.	Statutory minimum capital and surplus requirement .		118,700,549		123,793,739	160,381,882
4.	Total capital and surplus (Page 3, Line 33)		180,201,741		187,011,169	
	Income Statement (Page 4)	, ,	, ,	, ,		, ,
5.	Total revenues (Line 8)	755,212,636	952,467,973	977,590,457	992,094,189	1,284,582,226
6.	Total medical and hospital expenses (Line 18)				903,958,825	
7.	Claims adjustment expenses (Line 20)				40,621,164	
8.	Total administrative expenses (Line 21)		92,710,145		91,968,152	
9.	Net underwriting gain (loss) (Line 24)		(2,966,786)			
10.	Net investment gain (loss) (Line 27)					
11.	Total other income (Lines 28 plus 29)					
12.	Net income or (loss) (Line 32)					
	Cash Flow (Page 6)					
13.	Net cash from operations (Line 11)	(89,273,202)	20,658,329	20,522,575	(30,471,870)	(78,961,304
	Risk-Based Capital Analysis					
14.	Total adjusted capital	145,676,610	180,201,741	157, 155, 770	187,011,169	203,598,764
15.	Authorized control level risk-based capital					
	Enrollment (Exhibit 1)					
16.	Total members at end of period (Column 5, Line 7)	55,885	73,879	82,107	85,513	134,609
17.	Total members months (Column 6, Line 7)	708,959	898,761	993,051	1,036,507	1,650,248
	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0					
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)	96.3	88.3	89.7	91.1	96.4
20.	Cost containment expenses	4.3	3.8		2.5	
21.	Other claims adjustment expenses					
22.	Total underwriting deductions (Line 23)					
23.	Total underwriting gain (loss) (Line 24)	(7.4)	(0.3)	(6.3)	(2.4)	(6.5
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 13, Col. 5)	129,559,302	103,502,823	85 , 190 , 486	142,237,351	136,808,069
25.	Estimated liability of unpaid claims-[prior year (Line 13, Col. 6)]	144, 127, 431	95,760,344	94 , 128 , 595	154,237,097	166,119,736
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)					
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)					
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)	0	0	0		
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)			0	0	0
30.	Affiliated mortgage loans on real estate					
31.	All other affiliated					
32.	Total of above Lines 26 to 31	0	0	0	0	0
33.	Total investment in parent included in Lines 26 to 31 above.					

NOTE: If a party to a merger, have the two most recent years of	of this exhibit been restated due to a merger in compliance with the disclosure				
requirements of SSAP No. 3, Accounting Changes and	d Correction of Errors?	Yes [] No	0 []
If no, please explain:					

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by	States and	Territories
Allocated b	, otates and	16111101163

1. A 2. A 3. A 4. A 5. C 6. C 7. C 8. E	States, etc. Alabama		1	2	3	4	5	rect Business O 6 Federal	7	8	9	10
1. A 2. A 3. A 4. A 5. C 6. C 7. C 8. E	Alabama Alaska		•	2	3	7	J	-	,	O	3	10
1. A 2. A 3. A 4. A 5. C 6. C 7. C 8. E	Alabama Alaska							Employees Health	Life and Annuity			
2. A 3. A 4. A 5. C 6. C 7. C	Alaska		Active Status (a)	Accident and Health Premiums	Medicare Title XVIII	Medicaid Title XIX	CHIP Title XXI	Benefits Program Premiums	Premiums & Other Considerations	Property/ Casualty Premiums	Total Columns 2 Through 8	Deposit-Type Contracts
3. A 4. A 5. C 6. C 7. C		AL	N								0	
4. A 5. C 6. C 7. C 8. E		AK	N								0	
5. C 6. C 7. C 8. E	Arizona	AZ	N								0	
6. C 7. C 8. E	Arkansas	AR	N								0	
7. C 8. E	California	CA	N								0	
8. E		CO	N								0	
		-	N								0	
' 9. I		DE	N								0	
	District of Columbia .	-	N								0	
	Florida		N								0	
	Georgia		N								0	
	Hawaii		N								0	
		ID	N								0	
	Illinois		N								0	
		IN	N N								0 0	
	lowa		N N									
	Kansas		N N								0 0	
	Kentuckyl Louisiana		N N								0	
	Maine		N L		484,443						484.443	
	Maryland		L			·		·····			464,443	
	Massachusetts		N				•				0	
		MI	N			•					0	
	Minnesota		N								0	
		MS	N								0	
	Missouri	-	N								0	
	Montana		N								0	
28. N	Nebraska	NE	N								0	
29. N	Nevada	NV	N								0	
30. N	New Hampshire	NH	N								0	
31. N	New Jersey		N								0	
32. N	New Mexico	NM	N								0	
	New York		L	17 , 230 , 584	740,952,155						758 , 182 , 739	
34. N	North Carolina	NC	N								0	
35. N	North Dakota	ND	N								0	
	Ohio	-	N								0	
	Oklahoma	OK	N								0	
	_	OR	N								0	
	Pennsylvania		N								0	
		RI	N								0	
	South Carolina		N								0	
	South Dakota		N								0	
-			N								0	
	Texas		N								0	
	Utah	_	N								0	
	Vermont		N N					l			0	
	Virginia		N N								0 0	
	Washington West Virginia		N N								0	
	Wisconsin		N N								0	
	Wyoming		N			•	•				0	
	American Samoa		N								0	
		GU	N								0	
	Puerto Rico		N								0	
	U.S. Virgin Islands		N								0	
	Northern Mariana											
	Islands	MP	N								0	
	Canada	CAN	N								0	
	Aggregate Other	O.T.	WW	_	_	_	_	_		^	_	_
	Aliens		.XXX	0	0	0 0	0	0	0	0	750 667 100	0
60. F	Subtotal Reporting Entity Contributions for Employees	ployee	.XXX	17 , 230 , 584	741,436,598	0	0	0	0	0	758,667,182	0
	Benefit Plans		XXX	17 000 504	741 426 500	0	0		0		750 667 100	•
	Totals (Direct Busines		XXX	17,230,584	741,436,598	U	U	0	U	0	758,667,182	0
	DETAILS OF WRITE-		V///									
			XXX									
E0000			XXX						†			
	Summary of remaining					·		†				
	write-ins for Line 58 fro											
c	overflow page		XXX	0	0	0	0	0	0	0	0	0
	Totals (Lines 58001 th											
	58003 plus 58998)(Lir above)	ne 58	XXX	0	0	0	0	0	0	0	0	0

(a)	Active	Status	Counts:

/ Notive Status Sounts.	
L - Licensed or Chartered - Licensed insurance carrier or domiciled RRG	2
E - Eligible - Reporting entities eligible or approved to write surplus lines in the state	0
N - None of the above - Not allowed to write business in the state	55

⁽b) Explanation of basis of allocation by states, premiums by state, etc. Premiums are allocated based on residence of insured.


R - Registered - Non-domiciled RRGs......0
Q - Qualified - Qualified or accredited reinsurer......0


BCBSA Licensee


Regulated Insurance Company


Regulated BCBSA Licensee

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED










³ Wisconsin Collaborative Insurance Company is a joint venture 55% owned by Crossroads Acquisition Corp. and 45% owned by Aurora Health Care, Inc. (non-affiliate). Not consolidated for accounting purposes.

⁴ Anthem Workers' Compensation, LLC is owned 75% by Anthem Blue Cross Life and Health Insurance Company and 25% by HealthLink, Inc.





40.5

SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP PART 1 – ORGANIZATIONAL CHART

Regulated Insurance Company
Regulated BCBSA Licensee

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED






 $^{^{\}rm 6}$ Amerigroup Corporation holds a 2% interest in Highland Investor Holdings, LLC, and ATH Holding Company, LLC holds the remaining 98% interest.

 $^{^7}$ Alliance Care Management, LLC is 50% owned by Beacon Health Options, Inc. and 50% owned by Health Plus HP, LLC.

 $^{^8}$ TriaDD NY, LLC dba MyCompass is 25% owned by Alliance Care Management, LLC and the remaining 75% interest is owned by unaffiliated investors.


75% interest is owned by unaffiliated

SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP PART 1 – ORGANIZATIONAL CHART




BCBSA Licensee
Regulated Insurance Company
Regulated BCBSA Licensee

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED



- 12 Community Care Health Plan of Louisiana, Inc. is a joint venture 75% owned by Anthem Partnership Holding Company, LLC and 25% owned by Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana (non-affiliata)
- ¹³ CCHA, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Colorado Community Health Alliance, LLC (non-affiliate)
- ¹⁴ AMH Health, LLC is a joint venture 50% owned by MaineHealth (non-affiliate) and 50% owned by Anthem Partnership Holding Company, LLC
- ¹⁵ Momentum Health Partners, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Blue Cross and Blue Shield of North Carolina (non-affiliate)
- ¹⁶ GR Health Solutions, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Independence Blue Cross, LLC (nonaffiliate)
- ¹⁷ Community Care Health Plan of Nebraska, Inc. is a joint venture 95% owned by Anthem Partnership Holding Company, LLC and 5% owned by Blue Cross and Blue Shield of Nebraska, Inc. (non-affiliate).
- ¹⁸ APC PASSE, LLC (regulated entity) is a joint venture 49% owned by Anthem Partnership Holding Company, LLC and 51% owned by Arkansas Provider Coalition, LLC (non-affiliate).
- ¹⁹ Community Care Health Plan of Kansas, Inc. is a joint venture 90% owned by Anthem Partnership Holding Company, LLC, 5% owned by Blue Cross and Blue Shield of Kansas (non-affiliate) and 5% owned by Blue Cross and Blue Shield of Kansas City (non-affiliate).



²¹ Other 50% owned by ACO del Norte, LLC (non-affiliate)

OVERFLOW PAGE FOR WRITE-INS

Additional Write-ins for Assets Line 25

			Current Year		Prior Year
		1	2	3	4
				Net Admitted Assets	Net Admitted
		Assets	Nonadmitted Assets	(Cols. 1 - 2)	Assets
2504.	Prepaid Expenses	541,489	393, 152	148,337	1,248,377
2505.	State Income Tax Recoverable	337,902		337,902	0
2506.	New York Assessment	277,251		277,251	3,089,575
2507.	Blue Card Program Recoverable	250,938	250,938	0	116,361
2508.	Miscellaneous Receivables	112,175	112,175	0	801,862
2509.	Stop Loss Receivables (NY Regulation 4321, 4322 & 4327)			0	194, 103
2597.	Summary of remaining write-ins for Line 25 from overflow page	1,519,755	756,265	763,490	5,450,278

Additional Write-ins for Liabilities Line 23
--

			Current Year		Prior Year
		1	2	3	4
		Covered	Uncovered	Total	Total
2304.	Out of Area Program Payable	636,325		636,325	180,000
2305.	Miscellaneous Liability	115,602		115,602	261,456
2397.	Summary of remaining write-ins for Line 23 from overflow page	751,927	0	751,927	441,456